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7Summary
This report describes findings from anthropometric, bone mineral density, 
biochemical and dietary assessments in relation to bone health during follow-up 
consultations of biliopancreatic bypass with duodenal switch (BPD-DS) patients 
followed at the Department of Preventive Cardiology, Ullevål University Hospital 
from November 2006 to May 2007. 
The study population consisted of 65 BPD-DS patients, 55 women and 10 men, who 
had undergone surgery 2-5 years earlier. Average age was 40 years, and ranged from 
21 to 59. Mean BMI was 51 kg/m2 pre-surgery and 30 kg/m2 post-surgery, and ranged 
from 38 - 84 pre-surgery to 20 – 47 kg/m2 post-surgery. All patients in this study had 
achieved satisfactory weight loss at the time of follow-up assessments. The study 
population had a mean weight loss of 62 kg, and an average of 76 % of excess weight 
was lost.
Analyses showed a high incidence of increased bone turnover and fat soluble vitamin 
deficiency (vitamin A and D) after BPD-DS. No significant relationship between 
nutrient status and length of common channel was detected.    
Average bone mineral density (BMD) was within normal range, but 25-32 % had 
decreased levels (less than -1.0 SD of reference population) and men had significantly 
lower BMD than women. Patients with low BMD tended to be older, have lower BMI 
pre-surgery and lost less weight after the surgery. Reductions in BMI had the 
strongest correlation to BMD.  
Biochemical markers of bone turnover were increased in a large proportion with 
serum-PTH levels increased in 92 % and serum-I-CTP increased in 45 % of cases. We
found that a greater reduction in BMI was associated with higher levels of the bone 
resorption marker I-CTP, which indicated that the high rate of weight loss post-
surgery increases bone turnover. Our results showed moderate effect on BMD at 2-5 
8years post-surgery, but the significantly increased rates of bone turnover may affect 
BMD in the longer term.
We found no relationship between nutrient intake and nutrient status or BMD. Several 
factors may have affected these findings. Most importantly, we only obtained dietary 
registration from 45 % of the study population. 
No relationship was detected between supplement compliance and nutrient status or 
BMD. This could indicate that absorption of supplement derived nutrients may be 
even poorer than initially anticipated, however considering that supplement 
compliance was self-reported the reliability of this data may be poor. Nutritional 
monitoring over a longer time period, and for several years post-surgery, may be 
necessary to detect any relationship between such parameters. 
Our data is not sufficient to accept the H0 hypothesis which states that nutrient intake 
after BPD-DS is not associated with bone health. Further studies are needed to 
elucidate this, and we continue to emphasize the importance of ensuring patient 
compliance to post-surgery nutritional recommendations and follow-up procedures. 
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1. Background
1.1 Obesity
Body weight is a result of interactions between genetic, environmental and 
psychosocial factors, mediated trough the physiological factors; energy intake and 
energy expenditure. Adiposity occurs when energy intake exceeds energy expenditure 
over a prolonged period of time. An increase in energy intake or decrease in energy 
expenditure, which causes even a slight imbalance, may lead to obesity in the long-
term. The causal relationship is complex and there are several factors which affect 
energy balance.2 chapt 1.2
As illustrated in Table 1, the World Health Organization (WHO) recommends the use 
of the body mass index (BMI) as a tool to classify varying stages of obesity. BMI is 
calculated as weight (kg) divided by height squared (m2) and is frequently used in 
diagnostic setting.
Table 1. WHO table of BMI classification
Source 3 chapt 2, page 8
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BMI does not distinguish between weight from muscle and that from fat tissue, which 
may limit its applicability in determining health risk in some populations. Measuring 
waist circumference can be used as an indicator of abdominal, visceral obesity. 
Several studies have shown that the amount of visceral fat accumulation is a valid 
indicator of co- morbidities, independent of BMI. There is an increased risk of 
metabolic complications for men with a waist circumference above 102 cm, and 
women with a waist circumference above 88 cm .4 chapt 1, page 2. Measurement of 
hip circumference enables the assessment of gluteofemoral muscle mass and bone 
structure. Waist-hip ratio (WHR) also takes into consideration the accumulation of fat 
on the hips relative to that accumulated in the abdomen. This is useful when 
considering potential health implications of obesity. A tendency to accumulate surplus 
fat on the hips rather than in the stomach may protect from the development of co-
morbid conditions.4 chapt 22, page 282.
Morbid obesity is defined as a BMI above 40 or a BMI above 35 accompanied by 
existing co-morbid conditions. 5 This patient group has been determined to be eligible 
for obesity surgery.4 chapt 22, p 287.
1.1.1 Prevalence
Current data indicate a progressive rise in obesity worldwide. WHO reported an 
incidence of overweight and obesity among Norwegian men and women to be 31.4 % 
and 19.6 % respectively (data from 2002). In developed countries there is a higher 
prevalence of obesity in the lower socio-economic part of the population while the 
opposite is true for developing countries.4 chapt 1, page 1-20
In Norway, the proportion of obese men and women has increased significantly 
between 1960 and 1999. In this period there was an increase in average body weight 
of 9.1 and 3.7 kg in men and women respectively.6
Further studies confirm that average weight is still increasing. Data from the Oslo 
region show that 10 % of 30 year olds had a BMI above 30, 14 % among 40-year olds 
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and 18 % among 60-year olds. The incidence of obesity was slightly higher for men 
than women, especially within the younger population. Among women the prevalence 
of obesity was lower in the higher education group, whilst this difference was less 
apparent for the male population. There was a higher incidence of obesity among 
immigrants from non-western cultures compared to ethnic Norwegian women.7
The most recent population statistics for the Nordic countries is from 2006 and 
indicate a 9 % incidence rate in Norway for persons with a BMI above 30. It should 
be noted that only the Norwegian data was obtained from self-reported height and 
weight measurements and is the lowest reported incidence rate among the Nordic 
countries.8
The obesity epidemic does not only impose an increased prevalence of obesity, but 
also increasing degrees of this condition. The most rapid increase is seen in the 
subgroup classed as morbidly obese.3 chapt 2, page 20
1.1.2 Health implications of obesity
Obesity is increasingly being recognized as an important public health problem, and 
leads to high health care costs as well as economic productivity losses. The disease 
has detrimental effects, leading to premature mortality, morbidity, disability and 
reduced quality of life.4 chapt 3, page 28. The Framingham Heart Study showed that 
the risk of mortality increased by 1% for each extra 0.45 kg of excess weight between 
the ages of 30 and 42 years, and by 2% between the ages of 50 and 62 years.9 The 
severity and the duration of obesity is positively related to the risk of developing co-
morbidities.4, 10
Obesity increases the risk of developing the following conditions: 
 type 2 diabetes and insulin resistance
 metabolic syndrome
 cardiovascular diseases and coronary heart disease (including ischemic heart 
disease, angina pectoris and myocardial infarction) 
 hypertension
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 dyslipidaemia
 stroke
 various types of cancer (such as endometrial, cervical, ovarian, prostate, breast, 
colon, rectal, kidney, liver and gall bladder)
 end-stage kidney disease
 fatty liver disease
 osteoarthritis 
 pulmonary embolism
 deep vein thrombosis
 reproductive disorders, complications in pregnancy and polycystic ovary 
syndrome
 hyperuricaemia and gout
 gastro esophageal reflux disease
 gallbladder disease and gallstones
 pancreatitis
 low back pain
 breathlessness and sleep apnoea
 psychological and psychosocial problems
1.1.3 Dietary intake and obesity
Dietary intake is an important determinant of body weight, but the links between diet 
and obesity are difficult to determine due to methodological challenges in mapping 
dietary intake. Obesity occurs when energy intake exceeds energy expenditure over a 
prolonged period of time. According to the WHO there is sufficient evidence to 
conclude that the three main categories in habitual dietary intake which may increase 
the risk of consuming excess energy are; a diet high in energy dense foods (foods high 
in fat and/ or sugar and low in fibre); intake of sugary drinks and large portion sizes. 
Frequent consumption of fast-food may increase the risk of weight gain, whilst breast 
feeding and the traditional Mediterranean diet may prevent obesity. 4 chapt 5, page 
46-51
The progressive increase in availability of food supplies seen in the past 40 years is 
apparent. The proportion of energy derived from fat is higher than recommended in 
most European countries, whilst fruit, vegetables and dietary fiber intake is lower than 
recommended. This results in a tendency towards energy-dense diets in our part of the 
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world. The lower socio-economic subgroups have a higher occurrence of dietary risk 
factors for obesity.4 chapt 7, page 64.
1.1.4 Treatment of obesity
The overall aim in the management of obesity is to improve health and quality of life. 
This requires appropriately trained health professionals, who can manage associated 
medical complications as well as aiding weight loss. It will also require sufficient 
consultation time and long-term follow-up to ensure maintenance of weight loss.
WHO recommended the following aims of the treatment of obesity: A 5-10 % weight 
loss or maintenance of weight where the achievement of weight loss is not possible, 
reduction in waist circumference and changes in body composition by reducing fat 
percentage. It is important to reduce co-morbid conditions or prevent the development 
and/ or progression of these. A 5 % weight reduction is associated with some 
improvement in health parameters, while a 10 % reduction is likely to achieve 
significant improvement in blood pressure, blood cholesterol and triglyceride levels as 
well as improving the control of blood glucose levels in patients with insulin 
resistance and diabetes.4 chapt 22, page 282-284.
Methods of treatment
Conventional treatment for obesity involves lifestyle intervention, including dietary 
modification and/ or increasing physical activity with or without the aid of 
pharmaceutical agents. Pharmaceutical agents used in the treatment of obesity include 
Sibutramine and Orlistat. Sibutramine affects central regulation of food intake whilst 
Orlistat is a lipase inhibitor which reduces fat absorption.4 chapt 22, page 282-287.
There is a positive association between level of physical activity and the degree of 
weight loss sustained. However, physical activity as an isolated intervention only 
achieves modest weight loss (2-3 kg) hence a dietary component is likely to be 
necessary. There is convincing evidence that physical activity alone, diet alone and 
both components combined are all effective in the treatment of adult obesity. Physical 
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activity play a major role in maintaining weight-loss. New evidence suggests that 60 
min of physical activity per day, 5 days per week is necessary to maintain weight loss. 
It also suggests that frequent physical activity in every-day life is more important than 
structured exercising in the prevention of obesity. 4chapt 22, page 282-290.
Dietary treatment
Dietary treatment for obesity should restrict energy intake in order to achieve an 
energy deficit. Several methods have been tested for this purpose. Low-fat diets (≤ 30
% of energy from fat) have shown to achieve spontaneous weight loss and are also 
recommended for healthy normal-weight individuals because it is beneficial to health 
in the long term. A fixed energy deficit diet is useful in the development of diet plans. 
It is based on patients’ individual energy requirements and may for example aim to 
achieve an 500 kcal energy deficit per day. These dietary treatment plans may be 
helpful for patients who are making overall lifestyle changes with the intent of 
maintaining them in the long term. They also enable combined increase in physical 
activity and impose minimal adaptations on a persons life compared to other diets as 
they include readily available “normal food” and do not exclude any food groups. 
Evidence suggests that these methods increase patient compliance. Other dietary 
treatment methods include meal-replacement programmes especially designed portion 
based products to replace anything from one to all meals in a day. Such products are 
often used in very low or low energy diets (VLED and LED diets respectively). 
VLED diets have better short-term, but not long-term results. Low glycaemic index 
diets exclude foods which cause rapid postprandial glycaemia such as sugar, white 
bread and potatoes. The diet favours foods which are low in carbohydrates. 
High protein and low carbohydrate diets are popular dietary interventions in the 
weight management industry. Such diets are often composed of a high protein- and fat 
energy proportion, and severely restricted carbohydrate intake. These diets are 
associated with rapid weight loss and increased satiety, but also poor compliance and 
short term maintenance of weight loss. Determining the efficacy of the different 
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dietary interventions requires further research.4 chapt 5, page 46-51 and chapt 22, 
page 284-285.   
Another element in the lifestyle intervention treatment for obesity focuses on long-
term behavioural modification aimed at enabling patients to sustain changes in diet 
and physical activity patterns. This requires health professionals with good 
interpersonal skills. There is strong evidence that these methods combined with 
advice on diet, physical activity and health is the most effective conventional 
approach to maintaining weight loss.4 chapt 22, page 286
The 1991 National Consensus Development Conference on Gastrointestinal Surgery 
for Severe Obesity recommended that most patients seeking treatment for morbid 
obesity should first attempt conventional treatment before they are considered for 
obesity surgery.11 However currently such treatment programmes appear to show a 
persistent lack of success among those suffering with morbid obesity.12
1.2 Obesity surgery
Bariatric surgery is becoming increasingly popular as the treatment of choice for 
morbid obesity. A few years ago this type of surgery was performed at very few 
hospitals in Norway and they were not able to accommodate the increasing demand. 
As a result, several Norwegians traveled abroad to have the surgery. Today the 
capacity of Norwegian hospitals is increasing, but there is still a significant number 
who travel abroad to avoid long waiting lists. Patients who have not qualified for the 
operation in Norway may also travel abroad to have the procedure performed.  
Surgical treatment is the only intervention proven to maintain long-term significant 
weight loss (over 10 years) in the morbidly obese. This weight reduction is associated 
with significant metabolic benefits, particularly in patients with type 2 diabetes.3
chapt 22, page 287-290. Studies show good patient satisfaction and significantly 
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improved quality of life in this patient group, despite frequently reported side 
effects.13
1.2.1 Indications for obesity surgery
Obesity surgery is intended for high-risk morbidly obese patients. In order to qualify 
for obesity surgery patients must undergo medical, surgical, psychiatric and 
nutritional assessments by a multidisciplinary team. The American Association of 
Clinical Endocrinologists, the Obesity Society and American Society for Metabolic & 
Bariatric Surgery, Medical Guidelines for the Clinical Practice for the Perioperative 
Nutritional, Metabolic, and Non surgical Support of the Bariatric Surgery Patient 
2008, 1 have recommended several criteria for patient eligibility for obesity surgery. 
There is international consensus that bariatric surgery can be considered in patients 
with a BMI above 40, or a BMI above 35 accompanied by co-morbid conditions. 
Patients should be committed to comply with post-operative treatment guidelines 
including taking recommended supplements and attending follow-up consultations. 
Exclusion criteria include serious mental illness and/ or drug/alcohol misuse, 
reversible endocrine or other disorders being an important causal factor of the obesity, 
inability to comprehend risks, expected outcomes, alternatives and lifestyle changes 
required after bariatric surgery. Surgical treatment requires a multidisciplinary team to 
provide long-term follow-up of each patient.1, 3, 14
1.2.2 Obesity surgery techniques
Bariatric surgery includes both restrictive and malabsorptive methods. Some 
procedures involve either a restrictive or a malabsorptive change, while some involve 
both components. 
Gastric restriction causes weight loss by producing early satiety and limiting food 
intake. This method creates a small pouch (which is able to hold less than 20 ml). A 
modified version of this technique (the laparoscopic adjustable gastric band), uses an 
inflatable circumgastric band attached to a subcutaneous reservoir, which allows 
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access to a hypodermic syringe that injects or withdraws fluid, thereby tightening or 
enlarging the band. Gastric restriction operations require strict dietary compliance in 
order to achieve satisfactory weight loss because the narrow outlet does not inhibit 
intake of high energy liquids and soft foods. However, there is a lower risk of long-
term nutritional deficiencies because they do not entail as dramatic alterations in the 
gastrointestinal system. Reported excess weight loss after 3-5 years is 40-60 %, but 
after the initial period there is a slow regain and some patients do not achieve any 
long term weight loss after these procedures.1,4 chapt 22, page 287-288 
The most frequently performed gastric bypass surgery is the roux-en-Y gastric bypass 
(RYGB). A small proximal pouch (10-30 ml) is created from the stomach and 
connected to the jejunum 50cm from the ligament of Treitz. Most of the stomach, 
duodenum and a small portion of the jejunum are bypassed. This procedure limits 
food intake and produces some nutrient malabsorption. The distal gastric bypass 
procedure bypasses a greater length of the small intestine and may induce significant 
macronutrient malabsorption. RYGB achieves greater weight loss than purely
restrictive methods, but adverse effects such as dumping syndrome are frequent. 
There is a moderate risk of nutrient deficiencies, and this patient group require 
thorough dietary guidance and close follow-up.1, 4 chapt 22, page 287-288.
Obesity surgery is usually successful in inducing substantial weight loss, primarily by 
inducing a necessary reduction in energy intake. The Swedish obesity study (SOS 
study) is a prospective intervention study evaluating the medical outcomes of obesity 
surgery over a long period of time. After 8 years they reported an average weight loss 
of 16.3 kg, compared to no loss in a conventionally treated group.15
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Table 2: Common types of Bariatric surgery procedures.
Purely malabsorptive procedures Restrictive > Malabsorptive
Jejunoileal bypass
Roux-en-Y gastric banding 
(RYGB) standard, long-limb  
Jejunocolonic bypass
Purely restrictive procedures Restrictive < Malabsorptive
Gastric banding
Laparoscopic adjustable gastric 
band (LAGB) Biliopancreatic diversion (BPD)
Vertical banded gastroplasty BPD with duodenal switch
Silastic ring gastroplasty Very long limb RYGB
Table 2 illustrates the different types of bariatric surgery procedures, classified into 
groups according to degree of stomach restriction and malabsorptive component. The 
purely malabsorptive procedures, jejunoileal- and jejunocolonic bypass are no longer 
performed due to a high incidence of intolerable side effects.1
1.2.3 Biliopancreatic Diversion with Duodenal Switch
Biliopancreatic diversion (BPD)
The biliopancreatic diversion was developed by Scopinaro et al.16 It includes a 
subtotal gastrectomy which creates a 200 to 500 mL gastric pouch. Biliopancreatic 
juices are diverted to the terminal ileum 50 cm from the ileocecal valve, which 
significantly reduces the absorption of nutrients. An anastomosis between the 
proximal limb of the jejunum and ileum is made 50 cm proximal to the ileocaecal 
valve. The mixing of nutrients with digestive juices is in this way limited to the 50 cm 
common channel resulting in significant limitations of digestion and absorption. BPD 
causes weight loss primarily through energy and fat malabsorption and is associated 
with several micronutrient deficiencies, in particular iron and fat soluble vitamins as 
well as metabolic bone disease.10
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The biliopancreatic diversion with duodenal switch (BPD-DS)
The BPD was modified by Hess and Hess into the biliopancreatic diversion with 
duodenal switch (BPD-DS).17 This procedure maintains the pylorus and the first part 
of the duodenum. It is preferred by many amongst the obesity surgery techniques, 
because it results in the most significant weight loss.13, 18, 19 Its’ malabsorptive 
component prevents weight gain, but can also lead to severe malnutrition, particularly 
in cases with poor follow-up and/ or compliance to post-operative dietary 
recommendations. Stomach volume is reduced leaving approximately 20-30% of the 
stomach. The duodenum is cut just below the stomach and the small intestine is 
divided approximately 250 cm from the passage between the small and large bowel 
(ileocoecal passage). The lower part of the bowel is anastomosed to the remaining 
part of the stomach, making the new food channel. The remaining part of the bowel 
(biliopancreatic channel), is connected to the lower part of the small intestine, 50 to 
100 cm from the ileocoecal passage making up the common channel.1, 20 BPD-DS 
combines malabsorption with a moderate restriction of dietary intake and improves 
protein absorption and results in fewer side effects compared to the BPD.21 The BPD-
DS achieves up to 78 % excess weight loss at 18 years, but nutritional deficiencies are 
still relatively common (5-40% long-term). Alterations in bowel movements are 
frequent, with 3-5 movements, commonly offensive, occurring each day. The level of 
malabsorption is related to length of common channel.10
Figure 1. Illustration of the BPD and BPD-DS procedures .The duodenal 
switch is a modification of biliopancreatic bypass.
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Figure 2. Illustration of the difference between BPD-DS and RYGB bariatric 
procedures.
    
Health benefits
Bariatric surgery is considered the most effective treatment for co-morbid conditions 
in the morbidly obese22 BPD-DS has shown to result in rapid weight loss, with a mean 
percentage excess weight loss (% EWL) of 78 % sustained in the long-term.10 Excess 
weight is the amount of weight above a normal BMI (BMI above 25 kg/m2).
Reports show that weight loss, in particular visceral fat, leads to better management 
of insulin sensitivity and type 2 diabetes, obesity-related cardiomyopathy, cardiac 
function, lipid profile, respiratory function, disordered sleep, obesity-related 
infections, venous stasis, non-alcoholic liver disease, asthma, polycystic ovary 
syndrome, infertility and complications in pregnancy, joint problems (arthritis) and 
increases adiponectin levels. Subsequent reduction in abdominal pressure may also 
improve urinary incontinence, gastroesophageal reflux, hypertension, pseudotumor 
cerebri, venous stasis disease and hypoventilation. Less fat around the neck area 
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relieves obstruction too breathing and sleep apnoea. Most bariatric surgery patients 
also report improved psychosocial status and quality of life. 1
Bypassing the proximal bowel also improves the physiological responses to gut 
hormones involved in glucose regulation and appetite control. 23
Complications
Bariatric surgery is associated with several complications both in the early post-
operative period and in the long-term. Due to the nature of these procedures many are 
related to metabolic disturbances and several can lead to the need for re-constructive 
surgery.
Table 3. Complications related to bariatric surgery
Immediate complications Early complications Long- term complications
Anastomoses rupture Narrowing of anastomosis Malabsorption
 Diarrhoea
 Constipation
 Nausea, emesis
Dumping syndrome
Problems with wounds
 Infections, included fistulas
 Rupture
 Dysphagia
 Emesis
 Reflux
Conditions following malabsorption:
vitamin deficiency
iron deficiency
calcium deficiency
development of gall stones
Heart- and lung problems
- breathing
- pneumonia
- mycardial infarction
- deep veinous thrombosis
- lung embolism
Mechanical complications:
(a) ileus
(b) malfunction of uncoupled part 
of intestine
(c) incisinal hernia
(d) gastrointestinal bleeding
Death in connection with surgery 
(usually within 30 days)
Current knowledge regarding long-term nutritional complications following bariatric 
surgery is limited. This is especially true in relation to the BPD-DS technique. 
Nutrient deficiencies are common, and may become clinically significant if not 
recognized and treated. 24 Nutrient deficiencies previously identified in this patient 
group include protein, iron, vitamin B12, folate, calcium, fat soluble vitamins A, D, E 
and K, and other micronutrients. RYGB procedures commonly cause B12, iron and 
folic acid deficiencies. The deficiencies appear to be more severe in malabsorptive 
procedures such as BPD-DS. Research is needed to evaluate the clinical significance 
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of these deficiencies and to determine guidelines for supplementation.25 This section 
focuses on complications which are related to long-term metabolic complications in 
BPD-DS patients (as listed in table 2), relevant to bone health.
Nutritional Implications of BPD-DS 
Sustained weight loss after biliopancreatic diversion with duodenal switch is 
primarily due to decreased calorie absorption secondary to fat malabsorption. Initial 
weight loss is also due to moderate gastric restriction. Scopinaro et al found that only 
28 % of ingested fat and 57 % of ingested protein is absorbed after the BPD 
procedure. How much is absorbed after the BPD-DS procedure is unclear, but gastric
and pancreatic enzymes are mixed with bile only in the distal part of the ileum (the 
last 50-100 cm) also after this procedure. Fat malabsorption may lead to insufficient 
uptake of other essential nutrients such as essential fatty acids and the fat soluble 
vitamins A, D, E and K. This may have severe clinical consequences and alter 
calcium metabolism. Among the metabolic complications protein, vitamin and 
mineral deficiencies as well as liver damage have been reported.10, 25-27
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Table 4. Overview of reported metabolic complications associated with 
bariatric surgery.
Source: 1
According to Slater et al, 10 there is a progressive increase in the incidence and 
severity of A, D and K deficiency with time after BPD-DS. His team measured serum 
vitamins A, D, E, and K, zinc, parathyroid hormone, corrected calcium, and alkaline 
phosphatase levels in a cohort of patients who had previously undergone 
biliopancreatic diversion with or without duodenal switch. They found a mean % 
EWL loss of 48, 68, 59 and 59 % at one, two, three and four year post-surgery 
respectively. Serum vitamin A levels were low in 52 % of cases at one year and 69 % 
after four years, but no patients suffered from night blindness or visual abnormality. 
Vitamin K levels went from being abnormal in 51 % in the first to 68 % by the fourth 
year with unquantifiable levels (less than 0.1 nmol/L) in 42 % of cases. No patient 
had symptoms of excessive bleeding. All patients had normal levels of vitamin E one 
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year post-surgery and 96 % still had normal levels after four years. Serum zinc was 
abnormally low in 51 % at one year and 50 % after four years. Incidence of abnormal 
serum vitamin D levels was 57 % after one year and increased to 63 % in the fourth 
year. They also found that hypocalcaemia increased from 15 % in the first year to 48 
% four years post-operatively. Secondary hyperparathyroidism was seen in 31 % after 
one year and 69 % after four. Of the latter, 27 % had developed clinically significant 
hyperparathyroidism (serum parathyroid levels more than 50 % above the upper limit 
for normal). Some patients (6 %) also had raised alkaline phosphate levels. No 
patients suffered from bone pain.10
In other studies biochemical measurements have shown that low levels of serum 
albumin, creatinine, retinol, 25(OH)D and elevated levels of PTH are common. BPD-
DS with common channels less than 100 cm have a high incidence of complications 
and nutritional deficiencies.21, 28
Despite high patient satisfaction, the implication of the BPD-DS procedure may result 
in profound medical complications including, among others, malnutrition. It is 
therefore important to provide thorough and optimal follow up treatment for this 
patient group including long-term nutritional monitoring.10 Some may require 
chewable or liquid supplements to help adequate absorption. 28
Implications of BPD-DS DS for bone disease
Calcium and vitamin D deficiency, and elevated levels of PTH are common in morbid 
obesity. Up to 84 % of morbidly obese patients have vitamin D deficiency.28
Sequestration of vitamin D in adipose tissue and subsequent limited bioavailability 
may be an important cause of this. In addition lifestyle factors associated with obesity, 
such as an unbalanced diet and limited sun exposure could lead to nutrient 
deficiencies and disturbances in bone metabolism. Bariatric surgery may exacerbate 
these disturbances (and consequently changes in bone mass).29 Carlin et al, 2006 
highlighted the importance of identifying vitamin D deficiency pre-operatively and 
found an inverse correlation between 25(OH)D levels with BMI and PTH values. 30
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Osteomalacia, osteopenia, secondary hyperparathyroidism and increased bone 
turnover comprise the major metabolic bone disturbances which have been reported 
after bariatric surgery. A common scenario is that post-surgical weight loss is 
accompanied by an increase in s-PTH levels, a decrease in s-25(OH)D levels while 
corrected calcium levels tend to remain within normal limits.31 32 Sinha and Bockman, 
2007 noted that the degree of change in bone metabolism is probably related to 
amount of weight loss and malabsorption.14,33
In bariatric surgery there is a multifactorial aetiology to bone disease. Bypass 
procedures interfere with the normal mixing of intestinal contents with digestive 
juices which can lead to increased levels of fat in the intestinal lumen which in turn 
may decrease vitamin D absorption, leading to further decreases in calcium 
absorption. Steatorrhea also has a negative impact on calcium balance. In this 
condition calcium forms insoluble soaps with fatty acids in the gut. 14 The preferential 
sites for calcium absorption are primarily the duodenum and proximal jejunum. These 
are detached in the BPD-DS procedure. 34 When calcium absorption is decreased the 
body will maintain normal calcium levels by up-regulating PTH levels, increasing 
calcitriol and calcium resorption from bone. 35 Energy balance is also of importance 
for bone health. Profoundly restricted dietary intake, rapid weight loss, and impaired 
absorption of nutrients, is likely to implicate a high risk of developing metabolic bone 
disease after BPD-DS.30, 32, 35-37
The malabsorptive component of BPD-DS may also impair absorption of several 
other nutrients important in bone health, such as iron, vitamin C and vitamin K. For 
example when the distal small bowel is bypassed, magnesium deficiency may occur 
as a result of reduced absorption and chelation with unabsorbed fatty acids.38 In 
patients with shorter absorptive surfaces it becomes especially important to optimize 
nutrient intake. Guidelines on optimal supplementation for BPD-DS patients have not 
been established.28
BPD-DS patients are given a high protein diet in order to prevent protein 
malnutrition. It is therefore important to assess postoperative protein intake. Although 
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urinary calcium loss is unchanged by inclusion of protein and phosphorous rich foods 
such as meat, cereal, beans and dairy products, phosphorous increases the calcium 
content of the digestive secretions and therefore increases endogenous calcium losses 
in the faeces. Thus increasing consumption of protein rich foods results in net-
calcium loss, and this could exacerbate the risks of a low calcium diet. On the other 
hand, inadequate protein intakes compromise bone health and may contribute to 
osteoporosis.25
Thus BPD-DS patients depend on micronutrient supplementation to meet their needs. 
It is important to monitor compliance and adequate absorption. Crowley et al found 
that their gastric bypass patients who did not take vitamin D supplements, only 
achieved approximately half of required vitamin D intake.39, 40 In patients with 
gastrointestinal side effects or a history of calcium oxalate renal stones, calcium 
citrate may be better tolerated, alter urine acidity and often prevent further stone 
formation.28
Bariatric surgery and bone mineral density
Studies looking at malabsorptive bariatric surgery and BMD have found an incidence 
of 12.5 % with a T-score below -2.5, 39 % with a T-score between -1.0 and - 2.5. 
Severe hypovitaminosis D (25(OH)D < 8ng/mL) was seen in 34 % and 42 % had low 
hypovitaminosis D (s-25(OH)D = 8-20 ng/mL). The magnitude of weight loss 
correlated negatively with s-25(OH)D, calcium and phosphorus, and positively with s-
ALP levels. S-25(OH)D and calcium concentrations correlated positively with BMD. 
PTH, s-1.25(OH)2D3 and ALP concentrations correlated negatively with BMD. These 
characteristics were a reflection of the presence of secondary hyperparathyroidism, an 
accelerated conversion of 25(OH)D to 1.25(OH)D by the elevated PTH levels, and 
increased osteoblastic activity. They concluded that hypovitaminosis D and 
subsequent bone loss is common in patients who have undergone bariatric surgery. 
And these patients require rigorous vitamin D supplementation.41  
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Marceau et al investigated bone changes after BPD. They detected increased bone 
turnover and mineralization. Cortical thickness decreased, trabecullar bone volume 
increased. 10 years post surgery bone density was unchanged at the hip, but decreased 
by four percent at the lumbar spine. Elevated calcitriol was found to be a predictor for 
future bone loss. Elevated osteocalcin was associated with overall bone loss, and 
lower albumin levels were associated with bone loss at the hip. Lower calcium level 
was associated with bone loss at the lumbar spine. They concluded that bone was 
relatively tolerant to the metabolic changes after BPD, provided it was accompanied 
by close follow-up and treatment of metabolic disturbances and avoidance of 
malnutrition. They also concluded that the beneficial effects of surgery far outweigh 
the risk of post-operative bone disease.42
1.3 Bone Disease
Appendix 1 presents important dietary components related to bone metabolism, 
assessment methods of bone health including biochemical measurements and dual 
energy X-ray absorptiometry, and a brief outline of the physiology of bone 
metabolism
The prevention and treatment of bone disease is done in two stages during life. The 
primary prevention stage, during the first decades of life, is focused on maximising 
peak bone mass. Secondary prevention takes place in later stages of life and focuses 
on the prevention of excessive bone loss and subsequent osteoporosis. Both 
prevention stages have similar intervention strategies such as ensuring adequate 
nutrient intake and weight bearing physical activity. As discussed in appendix one, 
several important nutrients contribute to maintaining healthy bone. Many of these are 
co-dependent, interacting with each other, as well as genetic and environmental 
factors.43 Bone disease may be caused by nutritional deficiency and nutritional excess. 
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Osteopenia
Osteopenia is a term that describes low bone density. Even though osteopenia is not 
considered a disease, preventive measures should be taken since osteoporosis may 
develop if there is further losses in bone density.44
1.3.1 Secondary hyperparathyroidism (SHP)
Too much PTH production caused by increased activity of the parathyroid glands is 
known as hyperparathyroidism. When this occurs in response to low blood calcium, 
caused by another condition, the hyperparathyroidism condition is called secondary 
hyperparathyroidism. Secondary hyperparathyroidism is characterized by s-PTH 
above 8,5 pmol/L combined with 25(OH)D below 50 nmol/L and normal s-calcium 
levels (Ca2+ 2.15 – 2.55 mmol/L).45
A fall in serum-calcium results in secondary increase in PTH secretion. This condition 
is seen in malabsorptive states, osteomalacia, liver failure and chronic renal failure. 
1.3.2 Osteomalacia and rickets
Osteomalacia results from vitamin D deficiency or a disturbance in its metabolism. 
The main features include bone pain and tenderness, deformity and proximal muscle 
weakness. The biochemical changes include low plasma calcium levels, a reduction in 
plasma phosphate and a reduction in urine calcium excretion. However these changes 
depend on the underlying cause. A low plasma 25(OH)D level indicates vitamin D 
deficiency. Very low levels indicate nutritional osteomalacia, but not all patients with 
low levels develop bone disease. Diagnosis of osteomalacia is confirmed by a 
transiliac bone biopsy. The under calcified sections have an excessive thickness of 
osteoid and an increased coverage of the mineralized surfaces with unmineralized 
osteoid. 
Nutritional rickets may be a problem in Asian immigrants and in elderly people who 
are housebound. A vegetarian diet has also been linked to this disorder. A significant 
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number of elderly patients with femoral neck fracture have osteomalacia as well as 
osteoporosis.46 chapt 71, page 329-333
In osteomalacia the three classes of markers for osteoblast activity no longer correlate. 
PICP is normal, ALP is grossly elevated and osteocalcin is decreased. This is because 
the expression of osteocalcin is regulated by vitamin D. The increase in ALP may 
suggest that in the absence of vitamin D, the osteoblasts are halted the developmental 
phase immediately preceding matrix mineralization, which is characterized by ALP 
expression, leading to a situation where more cells than usual are producing the 
enzyme.47
Table 5. Overview of the different nutrients involved in bone metabolism 
and their role in the development of bone disease.  
Nutritional component Associated disease
deficiency Vitamin D Rickets/ osteomalacia
Vitamin C Scurvy
Copper Fractures (premature infants; PN*)
Zinc Delayed bone growth
Vitamin K ? osteoporosis
excess Vitamin A Hyperostosis
Ligamentous ossification
Vitamin D Idiopathic hypercalcaemia in infancy
Aluminium Aluminium osteodystrophy (dialysis and parenteral nutrition)
Fluoride Endemic
Iatrogenic
Cadmium Fanconi syndrome
Rickets/ osteomalacia
nutrition 
related
Calcium Osteoporosis
nutrition 
dependent
Vitamin D Rare forms of rickets
Pyridoxine Homocystinuria
* Parenteral nutrition (PN)
Source: 48
1.3.3 Osteoporosis
Osteoporosis is a systemic skeletal disease in which the bone density (amount of bone 
per unit volume) is decreased while the composition is unchanged (porous bone 
tissue). This occurs because of an imbalance between bone formation and resorption.
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Prevalence
The incidence of osteoporosis is increasing rapidly in the western world and is a 
major socio-economic problem. Every 3rd female and every 20th male will experience 
at least one osteoporotic fracture. The incidence is increasing exponentially with age 
in both males and females.46 chapt 38, page 198-202. Hip fractures are accompanied 
by up to 20 % reduction in remaining life expectancy: 50 % of patients who could 
walk prior to a hip fracture, are unable to walk without aid afterwards, a third will be 
completely dependant on care.43
In Norway osteoporosis has been recognized as a major public health problem with
one of the highest incidences of bone fractures in the world. There is a significant 
high incidence rate of femur, wrist and spine fractures and it is believed that 
osteoporotic fractures will reach epidemic proportions in the near future.44
Causes
The most important determinants of osteoporosis is peak bone mass and subsequent 
rate of bone loss, 49 but causes of osteoporosis are multifactorial, and a range of 
nutrients and foods may influence its development. Long-term deficiency or excess of 
one or more bone related nutrients, as well as changes in requirements following 
physiological and metabolic influences may contribute in the development of 
osteoporosis.43 In addition to a well balanced diet ensuring adequate calcium and 
vitamin D intake it is important to be physically active and avoid underweight.44
Unexplained osteoporosis is seen in younger males and females (idiopathic 
osteoporosis), and secondary to several diseases (for example induced by steroids, 
impaired gonad function, malabsorption, hypertyreosis, and immobilization). 
Diagnosis
The diagnostic criteria for osteoporosis involve both a clinical and statistical element. 
Clinically, the loss of bone is associated with micro architectural deterioration of bone 
tissue with a consequent increase in bone fragility and susceptibility to fracture. 
Statistically, the WHO defines osteoporosis as a T-score for bone mineral content of 
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more than 2.5 SD below the mean for young adults accompanied by at least one 
fragility fracture (a fracture that occurred as a result of slight trauma). It can be caused 
by several different pathogenetic mechanisms and therefore the biochemical 
indicators of bone metabolism will behave differently under several conditions that 
can all lead to osteoporosis. Increased bone resorption is reflected in pathological 
concentrations of bone collagen breakdown products e.g. 1-CTP.47
Bone fractures
In osteoporosis bone mass and bone strength is reduced to such a level that fractures 
occur without or after very little trauma (spontaneous fractures). Due to the structure 
and high metabolic activity, trabechular bone is most vulnerable. Common 
osteoporotic fractures are vertebral, forearm and femoral neck. The latter is 
considered the most important because it occurs most frequently and leads to 
considerable morbidity. Many osteoporotic fractures are frequent, lead to immediate 
disability, early and late mortality and considerably morbidity. Prevention of this 
disease is of considerable clinical and economic importance.46 chapt 38, page 198-202
Treatment
Increasing calcium intake does not have the same effect as estrogen, bisphosphonates 
and calcitonin therapy, and it is therefore not adequate as the only treatment for 
osteoporosis. However adequate calcium intake should be the basis of any other 
treatment.43
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Study rationale
The tremendous health consequences of morbid obesity and accompanying costs are 
considered important arguments for the surgical treatment of morbid obesity. 
However if the treatment contributes to morbidity from bone disease, one may argue 
that surgery could be counterproductive. Although nutritional complications are 
relatively well documented in respect to bariatric surgery in general, studies focusing 
on BPD-DS and bone health are limited, particularly in respect to long-term 
complications.50
Several studies have shown changes in bone metabolism after bariatric surgery. Such 
changes have included vitamin D deficiency, secondary hyperparathyroidism, 
hypocalcaemia and increased bone turnover.  It is believed that the severity of these 
consequences depend on the degree of weight loss and malabsorption. Of the bariatric 
procedures commonly performed today, BPD-DS causes the most severe weight loss 
and malabsorption. 14 However few studies focus on BPD-DS in particular and even 
fewer give insight into dietary habits which may affect bone health in this patient 
group. This study hopes to contribute information about medium term bone health (2-
5 years) following BPD-DS typical in Norwegian patients.
Study Aims
The primary aim of this study was to examine bone mineral density, nutrient intake 
and biochemical markers relevant to bone health in 65 BPD-DS patients 2 - 4 years 
post surgery, and identify potential long-term risk factors which may lead to 
disturbances in bone metabolism. 
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Research questions
1) Compare bone health status in patients and reference populations by measuring 
bone mineral density (BMD), using dual energy X-ray absorptiomentry (DXA) 
and by measuring biochemical markers relevant to bone metabolism.
H0 BPD-DS patients have BMD and biochemical markers within normal range 
compared to reference population.
H1 BPD-DS patients have decreased BMD, and altered biochemical markers 
compared to reference population. 
2) Compare anthropometric measurements to pre-surgical values, and correlate 
with BMD and biochemical markers relevant to bone health.
H0 Weight reduction after BPD-DS is not associated with biochemical markers or 
BMD
H1 The degree of weight reduction is positively related to biochemical markers 
and inversely related to bone mineral density.
3) Examine nutrient intake relevant to bone health, compare to current 
recommendations, BMD and biochemical markers of bone metabolism.
H0 Nutrient intake after BPD-DS is not associated with indicators of bone health. 
H1 Adequate nutrient intake is associated with protection against impaired 
biochemical markers and losses in BMD after BPD-DS. 
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2. Methods
The entire research project, from which this study is taken, is a result collaboration of 
two master students in clinical nutrition with medical personel at UUS, Department of 
Preventive Cardiology. These results have been divided between the two students and 
previous results have been presented in an earlier master thesis.
2.1 Arrangements
The two master students in clinical nutrition organised the procedures 
described here for all eligible patients who had undergone BPD-DS surgery at least 
two years earlier and up to five years earlier. The patients were all registered at the 
Department of Preventive Cardiology, UUS. The assessments, described in this study 
are part of the standard follow up procedure for this patient group in order to 
determine individual needs for medical and dietetic treatment. Routine blood samples 
required for the usual follow-up of the patients were obtained. Upon patient consent 
these were used in the study. 
The patients were invited to attend consultations and assessments all scheduled on the 
same day. To the extent possible, consultations were arranged early in the morning to 
make it convenient for the patients to combine with taking fasting blood tests at the 
UUS clinical chemistry and haematology laboratory. The patients were offered 
breakfast before and/ or in between consultations. Patients attended a consultation 
with the same physician (Serena Tonstad) and one of the two masters students in
clinical nutrition.
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2.2 Study assessment overview
Table 6: Study assessments
Study Assessment Overview
Consultation with professor Serena 
Tonstad
Bowel problems (including stool frequency), height, weight, BMI, waist 
circumference
Surgery details from patient records Surgery location, length of common channel, corrective surgery, pre-surgery 
anthropometric measurements 
Dual energy x-ray absorptiometry
(DXA)
Bone mineral density was measured  using the: Lunar iDXA, version 11.20.068 
(Human GE, Madison, Wisconsin) by a specialist in endocrinology, Dr. Johan 
Halse and his team at the Osteoporosis clinic, Pilestredet Park 7, Oslo Norway. 
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Biochemical measurements (blood-
test results for the following 
parameters)
s-calcium, ionised calcium, 1.25-dihydroxyvitamin D, 25-hydroxyvitamin D, 
Parathyroid hormone, bone specific ALP, osteocalcin, 1-CTP, phosphate, 
magnesium, albumin, s-retinol, cobalamin, folate
Subjective interview with master 
students in clinical nutrition
Interview assessing the following factors in relation to dietary intake: 
Supplement intake and compliance, Problems relating to food intake, 
Discomforts and disturbances in relation to digestion
Dietary registrations Dietary intake was assessed using a validated 7 day pre-coded food diary 
previously used in the Ungkost project.52 The diary was developed at the 
Department for Nutrition Research, University of Oslo.
2.3 Study population
2.3.1 Inclusion criteria
All patients who were registered for post-surgical follow-up after BPD-DS surgery at 
the Department of Preventive Cardiology, UUS, and had undergone surgery 2 years or 
more previously (up to 5 years), were invited to attend a routine follow-up 
consultation. Patients who attended their consultations were asked to allow routine 
assessment results to be used in this study. 
2.3.2 Exclusion criteria
There were no exclusion criteria. All patients known to be alive were invited. Patients 
who did not turn up for consultations after repeated invitations by post and telephone 
could not be included
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2.3.3 Ethical approval
Ethical approval was obtained from the Regional Committees for Medical Research 
Ethics, south-east Norway (REK), Postboks 1130, Blindern, 0318 Oslo. UUHs’ 
department for patient protection in research provided guidance on the development 
of forms for patient information and written consent.  No additional assessment was 
conducted solely for the purpose of research, as this would have required the use of a 
bio bank. Data was stored in the research server of UUS. Written consent was 
obtained from all study participants.
2.3.4 Anthropomentric and physical assessments
Dr. Serena Tonstad conducted routine assessments, which included medical history 
including gastrointestinal symptoms, anthropometric measurements and physical 
examination. The patients were weighed in the morning after a small meal (usually 
the breakfast provided following the blood tests). Patients were weighed bearing light 
indoor clothing without shoes. A Seca Alpha model 770 scale (Seca, Hamburg,
Germany, www.secaonline.com) was used.
Information about pre-surgical weight and BMI was obtained from the patients’ 
records and compared to the results from the follow-up assessments. A letter of 
individual recommendations was sent to each patient based on blood test and other 
results obtained within 8 weeks of the consultation. 
2.4 Bone mineral density (BMD)
Dual energy X-ray absorptiometry (DXA)
Bone mineral density was assessed by using DXA measurements 53, to identify 
potential long term nutrient deficiencies and disturbances in bone metabolism. 
DXA measurements were obtained by referral to an experienced laboratory at the 
Osteoporosis clinic, (Pilestredet Park 7, Oslo, Norway). Assessments were conducted 
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by an endocrinologist, Dr. Johan Halse and his specialist team using the: Lunar DXA, 
version 11.20.068 (Human GE, Madison, Wisconsin) 51. 
Z-score Results
The DXA measurement resulted in three different z-scores. All three were evaluated 
including total body bone mineral density z-score (TBBD), lumbar spine L1-L4 z-
score (AP spine) and dual femur bone density mean total z-score (dual femur). The z-
score compared BMD results to a reference population of age and gender matched 
controls.
2.5 Biochemical measurements
Results from biochemical measurements, relevant to bone health, taken during routine 
follow-up consultations, were obtained from the patients’ records. The following 
biochemical markers were considered in this study: Parathyroid hormone (PTH), 
1.25(OH)2D3, calcitonin, C-terminal telopeptide of type I collagen (1-CTP), bone 
specific- alkaline phosphatase (b-ALP). Other relevant biochemical measurements 
included serum levels of nutritional status including 25(OH)D, s-calcium albumin 
corrected (s-calcium alb corr), s-ionised calcium (s-ion calcium), s-phosphate, s-
cobalamin, s-folate and s-albumin levels.
Fasting venous blood had been collected at the clinical biochemistry laboratory, UUS, 
and analysed at the clinical chemistry and haematology laboratory at UUS, except the 
values for vitamin A, which were analysed at the nutrition laboratory at Aker 
University Hospital and vitamin D, calcitonin, PTH, 1-CTP and b-ALP which were 
analysed at the hormone laboratory at Aker University Hospital.
Parathyroid Hormone (PTH)
PTH was measured in frozen serum with a non- competitive immunoluminometric 
assay (ILMA) method obtained by using Immulite 2000 (Diagnostic Products 
Corporation (DPC), Los Angeles, CA. USA). At Aker Hormone lab they test for 
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intact PTH (1-84). This analysis has a high diagnostic accuracy and is able to 
differentiate between hypercalcaemia caused by hyperparathyroidism and 
hypercalcaemia caused by other diseases.
1,25-OH2 vitD and 25-OH vitD
The amounts of calcitriol and calcidiol in serum were both measured by using a 
competitive radioimmunoassay (RIA) method (Kit from DiaSorin, Stillwater, MN, 
USA).
Osteocalcin 
Osteocalcin was measured in serum using Brahms’ Luminoimmunanalysis (LIA), 
article number 58.1. Brahms Aktiengesellschaft, Neuendorfstr. 25, D-16761 
Hennigsdorf, 54
Bonespecific-alcaline phosphatase (b-ALP)
The enzymatic activity of bone specific alkaline phosphatase (b-ALP) was measured 
with Kit (Metra Biosystems Inc., Mountain View, Ca, USA).
Vitamin A
Vitamin A was measured by high performance liquid chromatography (Kit from Bio-
Rad Laboratories, California USA) on Perkin Elmer systems (Perkin Elmer, 
Massachusetts USA).
1-CTP
C-terminal telopeptide of type 1 collagen (1-CTP) was measured using the UniQ 
radium immunoassay kit from Orion Diagnostica, P.O.Box 83, FI-02101 Espoo, 
Finland. 55
Ionised calcium 
Ionised calcium was run on a machine from Roche called Cobas b 221 (This machine 
uses an ion- selective electrode).
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S-calcium, s-phosphate, s-magnesium and s-albumin
The results for the tests listed below were obtained on the Cobas Integra 800 (Roche 
Diagnostics):
Table 7. Biochemical parameters analysed using the Cobas Integra 800 
(Roche diagnostics)
Analysis methods on the Cobas Integra 800
magnesium Colorimetric method with Chlorophosphonazo III
phosphate Endpoint method
albumin Colorimetric endpoint method
total calcium Schwarzenbach with o-cresolphtalein complexone
Cobalamin and folate
For the analysis of haemoglobin a flowccytometer- based instrument called Sysmex
XE 2100 (The Sysmex Corporation, Kobe Japan) was used. Ferritin, vitamin B12 and
folic acid in serum was analyzed on Advia Centaur from Siemens
2.6 Dietary assessments
2.6.1 Consultation procedures.
The patients were scheduled for a one-hour visit with one of the two students to 
assess dietary habits and receive practical advice on food and supplement intake. 
These consultations included a subjective interview to assess dietary intake, and to 
make recommendations for adequate supplement, fluid and protein intake. To ensure 
standardised questions were asked, a structured interview guide was used in these 
consultations. (See appendix 2) The patients were also asked if dietary components 
had changed as a result of the DS surgery. Food intolerances in particular those 
regarding dairy products and high fat foods were assessed.
The structured interview also included detailed questions about supplement intake and 
compliance. The patients were first asked an open question about general supplement 
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intake; this was then cross-checked by asking specific questions about certain 
supplements recommended to BPD-DS patients. Information about brand, frequency 
and amount was obtained for each supplement. The interview also considered 
frequency of occasions when supplements were not taken as planned, and which 
supplements were missed out.
Patients were considered to have an adequate supplement intake if they complied with 
the minimum recommended intake of at least 4000 mg of calcium (4 tablets of 
calcigran forte), 750 µg vitamin D (one AfiD2 forte) and one vitamin-mineral 
supplement (Nycoplus multi or equivalent) per day. Other supplement intake was not 
considered in relation to bone mineral density in this report. 
2.6.2 Dietary records
After consultations, dietary intake was assessed using a 7-day (3 + 4) pre-coded, 
portion-size based food diary, which had been developed at the Department of 
Nutrition Research, University of Oslo were it was used in a population based 
epidemiological study, Ungkost, looking at dietary habits among the younger 
generations in Norway.52 (See appendix 3) This also included record of supplement 
intake. The diary had one booklet for each day which consisted of lists of food 
products and beverages. The lists were divided into bigger/smaller food groups (e.g. 
drinks, bread, vegetables, snacks, sweets). Every group had additional space to record 
intake of products which were not listed in the diary. For every food item/ beverage 
there were units listed (e.g. glass, slice, can, plate, and tub). The diary was filled in by 
recording amount of the relevant food item taken at a set time interval. The days were 
divided into five periods (6- 10 am, 10 am- 2 pm, 2- 6 pm, 6 - 10 pm and 10 pm- 6 
am). Accompanying the diary, was a booklet illustrating different portion sizes, as a 
guide to help the patients identify their respective portion sizes and ensure correct 
quantity of food item was recorded as accurately as possible. Patients also received 
detailed guidelines (verbal and written) on how to fill in the pre-coded food diary 
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(Appendix 4). Upon completion, the diaries were sent back to the clinic in a prepaid 
envelope.
The food diaries were scanned, optically read and proof read using Cardiff Teleform 
6.0 scan station. The result file was then imported into KBS, a nutrient calculation 
computer programme, to calculate energy and nutrient contents from the food diaries. 
KBS was also developed at the Department of Nutrition Research, University of 
Oslo.52
2.7 Statistical Analysis
All variables were examined using descriptive statistics including measures of central 
tendency, standard deviations and ranges. 
The Student t- test was used to compare continuously distributed variables to 
reference values. A paired samples t-test was used to test significant differences in 
anthropometric measurements, comparing pre-to post-operative values. Bone mineral 
density was compared between patients whose common channel length was => 100 
cm or <100 cm, and between those who had a common channel length => 70 cm and 
< 70 cm. An independent samples t-test was used to investigate the three BMD z-
scores according to gender.  
Because several variables were not normally distributed Spearman correlation 
analysis was used in the assessment of potentially related variables. The following 
variables were tested for correlation with the three mean z-score values for BMD and 
biochemical markers of bone metabolism; age, weight and BMI characteristics 
including changes in pre- and post surgical values, waist circumference at follow up, 
calcium intake from food and supplements, intake of vitamin D from food and 
supplements, intake of multivitamin supplements, stool frequency, s-PTH, s-25-OH 
vitD, s-1.25-OH vitD, s-osteocalcin, s-1CTP, s-bone specific-ALP, s-ionized calcium, 
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s-magnesium, s-phosphate, s-albumin and months since surgery. Significant 
correlations were presented. 
Bone Mineral Density Compared to Supplement Intake.
Relationship between supplement intake and BMD was investigated for correlation 
and differences between groups according to compliance with supplements. The three 
z-scores for BMD were also compared to calcium, vitamin D and general supplement 
intake using an independent samples t-test. Adequate intake was classified according 
to guidelines for supplement intake in this patient group. 
Multiple Regression of Significantly correlated variables
Multiple regression analysis was performed to identify the relative interrelationships 
between significantly correlated variables to the three BMD mean z-scores and serum 
levels of I-CTP.
A p-value of < 0.05 was considered statistically significant. The software program 
used was SPSS 15.0. 
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3. Results
3.1 Subjects
Among the patients registered for post-surgical follow-up, 77 had undergone surgery 
2-5 years prior to consultation dates. One patient was diseased, and ten patients did 
not attend follow-up consultations. Among the 66 patients who did attend, all 
consented to having their follow-up assessment results used in this study. One patient 
was excluded due to incomplete and suspected inaccurate measurements in several 
study parameters. This patient had incomplete biochemical measurements and was 
hospitalised for correctional surgery (to lengthen his common channel) during the 
post-surgery follow-up assessments. In total, twelve patients were excluded from the 
study. Thus the study population consisted of 65 BPD-DS patients (84.4 %of the total 
known patients), including 55 women and 10 men in total.  
3.1.1 Patient characteristics
Country of surgery
Table 8 presents country and city where patients had their BPD-DS surgeries, 
including the respective number of patients operated in each location.
Table 8. Surgery location
The majority had undergone surgery at Dr. Baltasars’ clinic in Alicante, Spain. 
Country of surgery number of patients (N=65)
Spain, Alicante 35
Norway, Førde 6
Belgium 9
Russia, Moscow 12
Germany 2
Sweden, Gothenburg 1
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Common Channel Length
Table 9 presents common channel length for the study population for whom the 
information was available.
Table 9. Length of common channel.
Length of common channel, cm n=62
mean (SD) 71 (17)
median (p25, p75) 65 (60, 75)
min-max 50-150
Information about common channel length was available in 62 cases. In three cases 
the medical records did not provide this information and the patients themselves 
stated that they had not been informed. Common channel length varied according to 
location of surgery and pre-surgical BMI. The shortest common channel was reported 
from surgery performed in Russia with 50 cm, and the longest was 150 cm from 
surgery performed in Germany. 
3.1.2 Results anthropometric measurements
Table 10 presents age at follow-up and pre- and post surgical anthropometric data.
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Table 10. Age and anthropometric characteristics
Characteristics total N=65 women n=55 men n=10
age, years
mean (SD) 40 (8.6) 40 (7.6) 39 (13.4)
median (p25,p75)* 38 (34.0, 46.5) 38 (34.0, 44.0) 38 (28.3, 51.0)
min- max. 21-59 26- 58 21- 59
weight pre-surgery, kg
mean (SD) 150.0 (27.1) 146.9 (26.2) 167,3 (27.0)
median (p25,p75)* 145.0 (130.5,163.0) 141.0 (129.0, 160) 156.5 (144.3, 193.5)
min- max. 108.0 – 235.0 108.0 – 235.0 140.0 – 215.0
weight at follow up, kg
mean (SD) 87.9 (15.3) 86.0 (15.5) 98.2 (9.6)
median (p25,p75)* 86.6 (77.5, 98.6) 85.0 (76.0, 96.0) 95.2 (92.4, 105.4)
min- max. 57.0 – 141.0 57.0 – 141.0 85.0 - 118.0
weight reduction, kg
mean (SD) 62,1 (56.8, 67.4) 60.8 (55.3, 66.3) 69.1 (49.9, 88.3)
median (p25, p75)* 56.7 (49.2, 75.5) 56.0 (49.0, 74.0) 64.0 (46.8, 98.7)
min-max 27.0, 135.0 27.0 - 135.0 33.3 – 103.6
excess weight loss, % 
mean (SD) 76 (72, 79) 76 (72, 80) 74 (65, 84)
median (p25, p25)* 76 (65, 85) 75.8 (61, 95) 77 (71, 118)
min – max 51 – 120 51- 120 52- 90
BMI pre-surgery, kg/m²
mean (SD) 51.1 (8.2) 51.1 (8.4) 50.5 (7.5)
median (p25,p75)* 50.6 (44.8, 55.9) 50.6 (45.0, 55.7) 49.1 (43.9, 58.5)
min- max. 38.0- 84.3 38.0- 84.3 39.6- 60.4
BMI at follow up, kg/m²
mean (SD) 29.9 (4.4) 29.9 (4.6) 29.7 (3.0)
median (p25, p75)* 29.5 (26.6, 32.7) 29.8 (26.5, 32.6) 29.2 (27.3, 33.0)
min- max. 19.5- 47.1 19.5- 47.1 25.1- 34.3
BMI reduction, kg/m2
mean (SD) 21.1 (7.1) 21.2 (7.1) 20.9 (7.9)
median (p25, p75)* 20.1 (16.6, 25.7) 20.3 (16.7, 25.3) 18.9 (14.1, 28.2)
min – max 7.8- 35.5 7.8- 48.4 9.4- 31.6
waist circumference, cm
mean (SD) 96 (12) 95 (12) 103 (11)
median (p25, p75)* 95 (89, 106) 95 (88, 102) 101(93, 115)
min- max. 72- 119 72- 119 90- 118
*p25 and p75 represents the 25th and 75th percentile respectively
Women had the greatest variation in anthropometrics, representing both the highest 
and lowest values for both weight and BMI, but the majority weighed between 110 
and 170 kg pre-surgery. Three patients had extreme values, with a weight above 215 
kg and one patient had a relatively low weight of 108 kg pre-surgery.
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All patients in this study had achieved satisfactory weight loss at the time of the 
follow up consultations. The study population had a mean weight loss of 62.1 kg and 
on average 75.6 % of excess weight was lost.
3.2 Results Bone Mineral Density (BMD)
DXA measurements were obtained in 57 cases, representing 88 % of the study 
population. Table 11 presents z-score results from DXA measurements of bone 
mineral density (SD of age matched controls) and compares men and women.
Table 11.  Bone mineral density (BMD) z-scores
DXA z-score results total group women Men p-value 
total body bone density (n=57) (n=48) (n=9)
mean (SD) -0.31 (1.30) -0.14 (1.22) -1.23 (1.44) 0.02 
median (p25,p75)* -0.20 (-1.25, 0.80) -0.10 (-1.08, 0.98) -1.80 (-2.45, 0.15)
min- max. -3.3 – +2.9 -2.9 - +2.9 -3.3 - +0.8 
lumbar spine L1-L4 (n=57) (n=48) (n=9)
mean (SD) - 0.74 (1.54) -0.58 (1.48) -1.64 (1.60) 0.055
median (p25, p75)* -0,80 (-2.00, 0.40) -0.80 (-1.80, 0.50) -1.40 (-3.15, -0.40)
min- max. -4.1-+2.9 -3.1-+2.9 -4.1-+0.8
dual femur bone density (n=56) (n=48) (n=8)
mean (SD) -0.38 (1.09) -0.35 (1.12) -0.58 (0.92) 0.591
median (p25,p75)* -0.45 (-1.10, 0.40) -0.40 (-1.08, 0.40) -0.60 (-1.55, 0.43)
min- max. -2.6-+3.5 -2.6-+3.5 -1.8-+0.5
*p25 and p75 represents the 25th and 75th percentile respectively
Mean total body bone density (TBBD) z-score for entire group indicated an average 
BMD in the low-normal range for the study population. The lowest TBBD z-score 
was measured in the male group, in which the mean z-score was much lower. Mean z-
score for lumbar spine in the male group was also much lower than in the female 
group. This group also represented the lowest measured value of -4.1 SD. 
Independent samples t-test showed significant differences in TBBD z-score between 
genders (p-value 0.02). There were no significant differences between genders in 
mean z-scores for lumbar spine L1-L4 or dual femur mean total.
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Table 10 shows number of patients with normal or abnormal BMD scores. A z-score 
between –1 and 1 was considered within normal range of reference population. A z-
score below -1.0 SD indicated a BMD lower than average compared to their peers and 
within the lowest 1 - 14 % of age matched controls. A z-score below -2.5 SD 
indicated a BMD lower than 99 % of the reference population. 
Table 12. Classification of BMD results
Total body bone density z-score group (n=57) Women (n=48) men (n=8/9*)
=> -1.0 39 (68 %) 36 (75 %) 4 (54 %)
< -1.0 14 (25 %) 12 (25 %) 5 (56 %)
=< -2.5 4 (7 %) 2 (4.2 %) 2 (22 %)
lumbar spine bone density  z-score
=> -1.0 32 (56 %) 30 (62 %) 4 (45 %)
< -1.0 18 (32 %) 18 (38 %) 5 (56 %)
=< -2.5 7 (12 %) 4 (8 %) 3 (33 %)
dual femur bone density z-score
=> -1.0 39 (69 %) 36 (75 %) 5 (63 %)
< -1.0 16 (29 %) 12 (25 %) 3 (38 %)
=< -2.5 1 (2 %) 1 (2 %) 0
*In the male group n=9 for total body bone density and AP spine, for dual femur n=8
Approximately 25-30 % had BMD results below normal. In the male group, the 
prevalence of low BMD was much higher at 56 %, but this difference was only
significant in TBBD z-scores. Only 7-12 % had z-scores above 1.0 SD
3.3 Results biochemical measurements  
Table 13 presents blood test results relevant to bone health for each gender. These 
were available for all patients. 
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Table 13. Biochemical measurements
Biochemical results
Nutrient status markers relevant in the maintenance of bone health
s-25(OH)D, nmol/L All (n=65) Women (n=55) Men (n=10)
mean (SD) 62.2 (27.4) 61.7 (25.5) 65.0 (38.0)
median (p25,p75)* 59.0 (39.5, 81.5) 60.0 (41.0, 81.0) 52.5 (37.8, 93.8)
min- max. 17.0 – 135.0 17.0 – 114.0 18.0 – 135.0
s-calcium albumin corrected, mmol/L (n=64) (n=54) (n=10)
mean (SD) 2.23 (0.17) 2.22 (0.17) 2.27 (0.12)
Median (p25, p75)* 2.25 (2.16, 2.33) 2.23 (2.17, 2.32) 2.32 (2.14, 2.36)
min – max 1.17 – 2.43 1.17 – 2.42 2.08 – 2.43
s-ion calcium active, mmol/L (n=61) (n=51) (n=10)
mean (SD) 1.24 (0.04) 1.24 (0.04) 1.25 (0.06)
Median (p25, p75)* 1.24 (1.22, 1.26) 1.23 (1.21, 1.25) 1.26 (1.21, 1.29)
min – max 1.14 – 1.34 1.16 – 1.36 1.14 – 1.33
s-phosphate, mmol/L (n=64) (n=54) (n=10)
mean (SD) 1.26 (0.17) 1.28 (0.15) 1.16 (0.25)
Median (p25, p75)* 1.28 (1.12, 1.37) 1.29 (1.17, 1.37) 1.15 (0.92, 1.31)
min – max 0.88 – 1.66 0.91 – 1.59 0.88 – 1.66
s-magnesium, mmol/L (n=62) (n=52) (n=10)
mean (SD) 0.88 (0.05) 0.88 (0.05) 0.88 (0.07)
Median (p25, p75)* 0.89 (0.84, 0.91) 0.89 (0.84, 0.91) 0.88 (0.84, 0.95)
min – max 0.75 – 1.01 0.76 – 0.98 0.75 – 1.01
s-cobalamin, pmol/L (n=63) (n=53) (n=10)
mean (SD) 233 (102) 238 (108) 209 (60)
Median (p25, p75)* 212 (168, 273) 213 (162, 276) 199 (172, 243)
min – max 101 – 684 101 – 684 116 – 328
s-folate, nmol/L (n=64) (n=54) (n=10)
mean (SD) 18.4 (9.4) 19.68 (9.38) 11.67 (6.26)
median (p25, p75)* 16.1 (10.7, 24.5) 17.55 (12.63, 25.60) 10.45 (7.55, 13.80)
min – max 4.8 – 45.7 6.00 – 45.70 4.80 – 27.30
s-vitamin A, mol/L (n=62) (n=53) (n=9)
mean (SD) 1.3 (0.5) 1.3 (0.5) 1.4 (0.5)
median (p25, p75)* 1.3 (1.0, 1.8) 1.3 (1.0, 1.7) 1.4 (1.0, 1.9)
min – max 0.2 – 2.5 0.2 – 2.5 0.7 – 2.0
s-albumin, g/L (n=64) (n=54) (n=10)
mean (SD) 42.2 (2.9) 41.7 (2.9) 44.7 (1.9)
median (p25, p75)* 42.0 (41.0, 44.0) 41.5 (40.0, 44.0) 44.5 (43.0, 46.0)
min – max 32.0 – 49.0 32.0 – 49.0 43.0 – 49.0
Markers of bone metabolism
s-PTH, pmol/L (n=64) (n=54) (n=10)
mean (SD) 13.7 (6.3) 14.2 (6.6) 11.0 (4.0)
median (p25,p75)* 12.6 (9.8, 16.3) 12.7 (10.3, 18.8) 11.2 (8.4, 13.4)
min – max 4.8 – 31.7 4.8 – 31.7 4.9 – 13.4
s-1.25(OH)2vitD, nmol/L (n=64) (n=54) (n=10)
mean (SD) 145.3 (47.4) 143.2 (48.6) 156.8 (40.2)
median (p25,p75)* 140.0 (115.3, 179.0) 131.0 (110.5, 175.3) 144.5 (130.5, 193.0)
min- max. 66.0 – 326.0 66.0 – 326.0 90.0 – 224.0
Bone resorption markers
s-1CTP, g/L (n=54) (n=44) (n=10)
mean (SD) 5.5 (1.8) 5.5 (1.9) 5.3 (1.4)
median (p25, p75)* 5.3 (4.3, 6.8) 5.4 (4.3, 6.9) 4.9 (4.3, 6.1)
min – max 1.5 – 10.7 1.5 – 10.7 3.6 – 8.1
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Bone formation markers
s-bone specific ALP, E/L (n=54) (n=44) (n=10)
mean (SD) 40.0 (15.3) 38.3 (15.2) 47.1 (14.6)
median (p25, p75)* 38.0 (28.8, 50.0) 36.0 (27.3, 47.5) 43.5 (38.5, 56.8)
min- max. 18.0 – 107.0 18.0 – 107.0 25.0 – 78.0
s-ALP, IU/L (n=64) (n=54) (n=10)
mean (SD) 89,3 (29.6) 86.8 (29.1) 102.9 (30.0)
median (p25, p75)* 84.0 (68.5, 103.3) 78.0 (67.3, 101.0) 95.5 (84.5, 126.8)
min – max 49.0 – 207.0 49.0 – 207.0 50.0 – 154.0
s-osteocalcin, nmol/L (n=54) (n=44) (n=10)
mean (SD) 1.9 (0.8) 1.8 (0.8) 2.1 (0.7)
median (p25,p75)* 1.8 (1.5, 2.2) 1.7 (1.5, 2.1) 2.2 (1.9, 2.8)
min- max. 0.5 – 5.4 0.5 – 5.4 0.7 – 2.9
*p25 and p75 represents the 25th and 75th percentile respectively
Table 14 shows the prevalence of abnormal results in relation to reference values.
Table 14. Prevalence of abnormal biochemical results 
Biochemical results - abnormal values no of cases (%) Reference
Nutrient status markers
s-25(OH)D (n=65, f= 55, m= 10) 14 (23 %) < 37 nmol/L
s-calcium albumin corrected (n=64, f=54, m=10) 16 (25 %) >2.17 mmol/L
s-ionized calcium active (n=61, f=51, m=10) 1 (2 %) <1.15 mmol/L
s-phosphate (n= 64, f= 44, m= 10) 11 (17 %) > 1.4 mmol/L
s-magnesium (n= 62, f= 52, m= 10 ) 0 < 0.71 mmol/L
s-ferritin (n=64, f=54, m=10) 10 (16%) men <25, women <10 mol/L
s- vitamin. B12 (n= 63, f= 53, m= 10) 7 (11 %) <140 pmol/L
s-folate (n= 64, f= 54, m= 10) 1 (2 %) < 6 pmol/L
s-vitamin A (n= 62, f= 53  m= 9 ) 40 (66 %) < 1,44 mol/L
s-albumin (n= 64, f= 54, m= 10) 9 (14 %) < 40 g/L 
s-total protein (n= 64, f= 54, m= 10) 7 (11 %) < 64 g/L
Markers of bone turnover
s-PTH (n= 64, f= 55 m= 9 ) 60 (92 %) > 5,7 pmol/L
s-1,25(OH)2vitD (n= 64, f= 54, m= 10) 16 (28 %) >  169 pmol/L
Markers of bone resorption
s-1CTP (n= 53, f= 44, m= 9) 24 (45 %) men >5,0 ug/L women >5,6 g/L
Markers of bone formation
s-b-ALP (n= 54, f= 44, m= 10) 37 (69 %) men > 41 E/L women > 31 E/L
s-Osteocalcin (n= 54, f= 44, m= 10) 1 (2 %) < 3,4 nmol/L
Table: Number of cases and frequency of abnormal biochemical markers, (above or below reference values stated for each).
Mean 25(OH)D values for entire group was normal, but there was a wide range in 
these values and some patients had very low levels. Fourteen patients (22 %) had low 
vitamin D, while none had values above the normal range. The female group had 
slightly lower values compared to the male group. Serum levels of the active vitamin 
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D metabolite 1.25(OH)2D3 was within normal range in 72 % of the study population, 
the remaining 28 % had increased levels, indicating increased bone turnover.  
Forty patients (66%) had serum vitamin A levels below the reference range. Mean 
albumin corrected s-calcium was in the normal range, but 25 % presented with sub-
normal levels. There was no significant difference between genders. 
There was a high prevalence (92 %) of increased PTH. The female group had a 
slightly higher mean value compared to the male group. Only five patients (8 %) had 
normal s-PTH levels. One patient had a I-CTP level below normal, while twenty-four 
(44 %) had increased levels. 
The majority (69 %) had increased serum bone-specific alkaline phosphatase. The 
remaining 31% had normal levels. S-bone specific ALP was higher in the male than 
in the female group. Mean s-osteocalcin was mostly within normal range and only 
two patients had abnormal levels. One patient had a value below normal and one 
patient had significantly increased levels. 
3.4 Results Nutrient Intake
3.4.1 Dietary interview regarding supplements
Table 15 presents results on supplement intake as reported during consultations. 
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Table 15. Results of self-reported supplement intake 
Self-reported supplement intake no of patients (N=65) study population, %
calcium supplementation1
recommended dose or more taken (at least 2000mg calcium per day) 31 48
some calcium taken2 53 81
no calcium supplementation 11 17
high-dose vitamin D supplementation3
recommended dose taken (750g D2 per day) 43 66
more than recommended dose taken 6 9
some high-dose vitamin D supplementation taken4 52 80
no high-dose Vitamin D supplementation 13 20
multivitamin with mineral supplementation5
recommended dose or more taken (at least 2 tablets per day) 36 55
at least one tablet per day taken 55 85
no multivitamin & mineral supplementation 10 15
recommended dose of cod liver oil with vitamin A and D taken6 4 6
half of recommended dose cod liver oil taken 10 15
other omega 3 supplement, unregistered brand 5 8
intake of omega 3 supplement with B vitamins7
recommended dose taken (two capsules per day)8  12 19
at least one capsule per day9 22 34
more than recommended dose taken 1 2
no supplements taken 7 11
other supplements than recommended (unspecified) 37 57
1Nycomed calcigran forte, one tablet contains 500 mg calcium carbonate and 10 g cholecalciferol (vitamin D3), produced by Nycomed Pharma 
AS. Dosage recommended to our patients was 2  2 tablets per day or equivalent calcium supplementation. 
2At least 500 mg of calcium (one calcigran forte tablet or equivalent) taken per day.
3High-dose vitamin D supplement, AFI-D2 forte from Nycomed Pharma, containing: Ergocalciferol (vitamin D2) 0,75 mg equivalent to vitamin D 
30 000 NE per tablet. Our patients were recommended taking one capsules per day.
4One or more tablets of AFID2 forte taken at least once per week 
5Nycomed Nycoplus multivitamin and mineral supplement or equivalent. (One tablet Nycoplus Multi contains: vitamin A 500g, vitamin D 5g, 
vitamin E 10mg, B1 1.4mg, B2 1.6mg, B3 18mg, B6 2mg, B5 6mg, B12 1g, folic acid 200g. vitamin C 60mg, zinc 15mg, copper 2mg, iodine 
150g, manganese 2.5mg, chromium 50g, selenium 50g, iron 14mg, magnesium 100mg) Our patients were recommended taking 1  2 tablets 
per day.
6Møllers tran or Møllers Dobbel: Cod liver oil either 5ml liquid or 2 capsules containing 10g vitamin D, 250g vitamin A and 10mg vitamin E 
(two capsules also contain 300mg EPA, 300mg DHA, 5 ml liquid contains 600mg DHA and 400mg EPA). These are standard doses which were 
also recommended to our patients. 
7Omega 3 supplement (Møllers godt for hjertet) with 450mg of omega 3 (200mg EPA, 200mg DHA), 100μg folate, 1mg vitamin B6, 1μg vitamin 
B12 and 5mg vitamin E per capsule. 
8Recommended dose was 2 capsules of the omega 3 supplement with B vitamins (møllers godt for hjertet) per day
9 One or more capsules of the omega 3 with B vitamins taken per day
Most patients reported using supplements. The majority took calcium, vitamin D and 
a combined multivitamin & mineral supplement to some extent, but only twenty six 
patients (40 %) reported taking at least the recommended dose of all three of these 
supplements. Less than half reported taking at least the recommended dose of calcium 
per day, but 77 % reported taking 1000 mg of calcium or more each day. Forty three 
patients (66 %) complied with the recommended daily high-dose vitamin D 
supplementation of 750g, while 5 % took more than recommended (they took two 
tablets which provided 1500 g per day). Thirteen patients (20%) took no high-dose 
vitamin D supplement. Table 14 also presents content of vitamin and minerals in the 
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recommended multivitamin & mineral supplement, Nycoplus Multi. Approximately 
half of the study population (55%) took the recommended dose (two tablets) of this 
supplement, while fifty five patients (85%) took at least one tablet per day. Few 
patients took the recommended dose of cod liver oil with vitamin A, D and E, but ten 
patients took half the recommended dose. A large proportion (57 %) took other 
unspecified supplements in addition to and/ or instead of recommended 
supplementation. Two patients reported taking calcium citrate in addition to or instead 
of Calcigran forte. This intake was included in their estimated calcium intake. Seven 
patients (10.8 %) reported taking no form of supplementation at all.
Table 16 presents average intakes of calcium and high-dose vitamin D.
Table 16. Intake of calcium and vitamin D from supplements reported in 
structured interview (Calcigran forte or equivalent and AFI-D2 forte). 
Calcium and vitamin D intake from 
self-reported supplementation total N=65 women n=55 men n=10
calcium, mg
mean (SD) 1352 (850) 1396 (847) 1107 (866)
median (p25,p75)* 1500 (1000, 2000) 1800 (1000, 2000) 1000 (54, 2000)
min- max. 0 – 3000 0 – 3000 0 – 2000
vitamin D, g
mean (SD) 635 (424) 655 (410) 525 (506)
median (p25,p75)* 750 (375, 750 750 (750, 750) (0, 750)
min- max. 0 – 1500 0 – 1500 0 – 1500
*p25 and p75 represents the 25th and 75th percentile respectively 
The female group had slightly higher mean calcium and vitamin D intakes than the 
male group. Median vitamin D intake however, was similar in both groups. 
3.4.2 Dietary Records
We obtained dietary records from only twenty-nine patients. Hence we present data 
on food and nutrient intake from less than half (45 %) of the patients. Table 17
presents macronutrient intakes from dietary records, excluding supplements. 
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Table 17. Average daily macronutrient intake from dietary registrations. 
Macronutrient intake from food & beverages tot group n=29 women n=25
energy, kJ
mean (SD) 10914 (3705) 10675 (3597)
median (p25,p75)* 10408 (8485, 12709) 10408 (8485, 12346)
min- max. 4577 – 23629 
protein,, g
mean (SD) 105 (31) 103 (32)
median (p25,p75)* 105 (84, 122) 101 (81, 122)
min- max. 30 – 168 30 – 168
protein, %
mean (SD) 16.7 (3.3) 16.7 (3.3)
median (p25,p75)* 16.7 (14.4, 18.5) 16.7 (14.5, 18.1)
min- max. 108- 235 11.0 – 25.1
fat, g
mean (SD) 117 (49) 116 (51)
median (p25,p75)* 109 (83, 157) 109 (83, 145)
min- max. 26 – 296 26 – 296
fat, %
mean (SD) 38.9 (6.2) 39.0 (6.6)
Median (p25,p75)* 40.0 (36.4, 43.5) 40.0 (35.4, 43.9)
min- max. 20.9 – 48.5 20.9 – 48.5
SFA, %
mean (SD) 16.3 (2.5) 16.3 (2.6)
Median (p25,p75)* 16.7 (14.5, 18.3) 16.7 (14.5, 18.3)
min- max. 9.2 – 20.6 9.2 – 20.6
MUFA, %
mean (SD) 12.8 (2.3) 12.9 (2.4)
median (p25, p75)* 12.7 (11.6, 13.8) 13.4 (11.7, 14.1)
min- max. 6.6 – 17.6 6.6 – 17.6
PUFA, %
mean (SD) 7.0 (2.2) 7.0 (2.3)
median (p25, p75)* 7.1 (5.3, 9.1) 7.1 (5.0, 9.2)
min- max. 3.3 – 11.2 3.3 – 11.2
CHO, g
mean (SD) 264 (95) 275 (91)
median (p25, p75)* 247 (194, 271) 262 (209, 288)
min – max 142 – 550 168 – 586
CHO, %
mean (SD) 43.1 (7.6) 43.2 (8.0)
median (p25, p75)* 42.6 (38.8, 46.6) 41.7 (38.8, 46.2)
min- max. 29.2 – 68.0 29.2 – 68.0
fibre, g
mean (SD) 18.3 (6.0) 17.9 (5.8)
median (p25, p75)* 18.0 (14.4, 21.6) 17.8 (14.4, 21.6)
min – max 8.0 – 35.9 8.0 – 35.9
sugar, %
mean (SD) 10.0 (7.5) 10.1 (7.8)
median (p25, p75)* 7.8 (5.8, 12.2) 7.9 (5.8, 12.2)
min- max. 1.8 – 38.1 1.8 – 38.1
*p25 and p75 represents the 25th and 75th percentile respectively
Results show great variations in energy intake. Mean energy intake was high. The 
large majority however had an average daily energy intake between 7000 and 14000 
kJ per day. One patient had an energy intake which was over 6400 kJ higher than any 
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of the others at 23629 kJ per day. Energy contribution from fatty acids was 
particularly high with a saturated fat intake contributing to 16.3 % of energy intake. 
One quarter of CHO intake was provided from added sugar which contributed to 10 
% of energy intake. 
Table 18 presents data on micronutrient intake from 3+4 day dietary registrations, 
(excluding supplements). 
Table 18. Average daily micronutrient intake. 
Nutrient intake from food and beverages tot group n=29 women n=25
vitamin D, g
mean (SD) 5.5 (4.3) 5.7 (4.6)
median (p25, p75)* 4.5 (3.0, 6.6) 4.5 (2.8, 7.2)
min – max 0.65 – 18.8 0.64 – 18.81
vitamin A, RAE
mean (SD) 1243.4 (624.7) 1263.2 (661.3)
median (p25, p75)* 1048.0 (872.0, 1599.0) 1048.0 (888.5, 1645.0)
min – max 267.0 – 3714.0 267.0, 3714.0
calcium, mg
mean (SD) 1213.4 (464.0) 1189.1 (476.7)
median (p25, p75)* 1162.0 (778.5, 1559.0) 1158.0 (742.0, 1559.0)
min – max 406.0 – 2191.0 406.0 – 2191.0
magnesium, mg
mean (SD) 341.8 (92.8) 337.8 (94.5)
median (p25, p75)* 346.0 (280.5, 383.0) 345.0 (280.5, 383.0)
min – max 123.0 – 590.0 123.0 – 590.0
*p25 and p75 represents the 25th and 75th percentile respectively
Average micronutrient intake from food and beverages mostly met the Norwegian 
governments’ (shdir) Recommended Dietary Intake (RDI), apart from vitamin D , 
which was slightly lower than these recommendations. Micronutrient intake also 
varied greatly between individuals. 
Table 19 presents supplement contribution of average vitamin A, vitamin D, calcium 
and magnesium intake as recorded in 7 day dietary registration. Of the 29 diaries 
returned, none answered all the questions about supplement intake, hence (n) for each 
micronutrient is stated. Table includes both genders.
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Table 19. Average daily supplement contribution to vitamin A, vitamin D, 
calcium and magnesium intake from dietary registrations.
Nutrient intake from recorded supplements mean (SD) median (p25, p75) min-max
vitamin D, μg (n= 22) 673  (589) 719  (57, 860) 10-2189
calcium, mg (n = 21) 1537  (789) 1857  (1000, 2000) 0- 2857
magnesium, mg (n= 21) 149  (46) 157  (100, 200) 86- 206
vitamin A, RAE* (n= 22) 951  (569) 840  (643, 1144) 0- 3025
* 1 RAE = 1 μg retinol or 12 μg β-carotene
Supplements were the main source of vitamin D, vitamin A, calcium and magnesium.
Table 20 presents contribution of food groups to nutrients, excluding that from 
supplement intake, from dietary registrations.
Table 20. Average daily nutrient contribution from food and beverages.
Percent contribution of food groups to nutrients (n=29)
energy 
%
protein 
%
fat 
%
SFA 
%
MUFA 
%
PUFA 
%
CHO 
%
sugar 
%
fibre 
%
vitamin 
A
vitamin 
D Ca
M
g
Bread 12 9 3 1 2 7 23 - 34 - - 2 18
Other cereal products 6 7 4 5 3 4 8 1 9 4 - 8 6
Cakes 5 2 6 6 5 7 6 10 4 4 5 2 3
Potatoes 2 1 - - - - 4 - 7 - - - 4
Vegetables 2 2 - - - 1 3 1 14 12 - 2 5
Fruit & berries 6 1 - - - 1 13 7 18 1 - 3 8
Meat, blood & offal 13 28 18 17 24 9 2 - - 28 - 3 9
Fish & shellfish 3 8 3 1 3 4 1 1 - 1 32 1 4
Egg 2 4 3 2 4 2 - - - 4 9 1 1
Milk, cream products 
etc. 10 12 8 12 7 1 10 10 - 8 9 32 10
Cheese 7 13 11 16 10 2 - - - 11 1 30 4
Butter, margarine, 
oils 11 1 27 22 21 51 1 1 - 21 42 - -
Sugar & sweets 9 3 7 8 8 4 13 35 1 1 - 4 8
Drinks 8 3 3 4 2 - 11 33 - 3 1 8 11
Nuts and seeds 2 2 3 1 5 6 1 - 3 - - - 4
Miscellaneous 3 2 3 3 4 2 4 1 10 1 - 2 4
Bread and bread products contributed most to energy intake, but meat and meat 
products were also important energy sources. Other foods frequently consumed 
included dietary fats such as oil, butter, margarine and mayonnaise based sauces, milk 
products, sweets and chocolate. Popular spreads were cheese, cottage cheese and meat 
spreads such as liver pate, ham and salami. Fruit and vegetable intake varied between 
individuals, but generally intake was low.
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Dairy products including milk, cheese and cream based products contributed the most 
to calcium intake and were important sources of magnesium. Bread was, however, the 
main food source of magnesium. Important sources of vitamin A were meat and meat 
products, dietary fats, and, to some extent, cheese. Dietary fat, in particular margarine, 
was the main source of vitamin D followed closely by fish and fish products of the 
more fatty varieties. 
3.5 Relationships between nutrients, biochemical 
measurements and BMD measurements
3.5.1 Nutrient intake, nutrient status and bone health
No significant relationship was found between nutrient intake from dietary recordings 
and bone mineral density or markers of bone turnover (data not shown). Calcium and 
vitamin D status markers were not associated with BMD or bone turnover (data not 
shown). Compliance to supplement intake did not correlate with any indicators of 
bone health (data not shown). 
3.5.2 BMI reduction               
Table 21 presents results from t-tests testing differences between patients with a BMI 
reduction of less than the median (=<20.1 kg/m2) and those with a reduction above 
the median (>20.1 kg/m2).  
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Table 21. Comparison of patients with BMI reduction above or below 
median.  
BMI reduction mean
BMI reduction 
7.8 - 20.1 kg/m2
BMI reduction 
20.2-35.5 kg/m2 
p-
value
mean 
difference
Gender (N=65, f=55, m=10) f=26, m=6 f=29,m=4 0.533 -0.057
Age, years (N=65) 39.65 41.97 37.39 0.035 -4.473
BMI pre-surgery, kg/m2 (N=65) 51.06 45.58 56.37 0.000 10.605
common channel, cm (n=62) 71.21 76.77 65.65 0.011 -10.740
Waist at follow up, cm (N=65) 95.95 95.88 96.03 0.859 -0.525
s-vit.B12, pmol/L (n=63) 233.24 206.55 259.09 0.042 52.243
I-CTP, ug,L (n=54) 5.48 5.04 5.86 0.063 0.902
TBBD, z-score (n=57) -0.31 -0.796 0.094 0.017 0.814
AP-spine, z-score (n=57) -0.74 -1.112 -0.435 0.153 0.585
Dual femur, z-score (n=56) -0.38 -0.764 -0.071 0.026 0.633
Variables related to weight and weight change, were significantly related to bone 
mineral density, and BMI reduction was significantly correlated to BMD. Those who 
had lost less weight were older, they had a lower initial BMI and a longer common 
channel. They also tended to have lower I-CTP. In relation to BMD those who lost the 
most weight had higher BMD z-scores for total body and dual femur but not for AP 
spine. 
3.5.3 Bone mineral density
Table 22 compares patients with a total body bone density (TBBD) z-score equal to or 
above and below -1.0 SD.
Table 22. Comparison of patients with normal or abnormal total body bone 
density z-scores.
TBBD z-score above or 
below -1.0 SD mean
mean
<-1.0 SD
mean
=>-1.0 SD
p-
value
mean 
difference
95% confidence 
interval
Gender f=12, m=5 f=36, m=4 0.068 -0.194 -0.403 0.015
Age, years 39.7 (N=65) 43.4 (n=17) 37.1 (n=40) 0.007 -6.337 -10.829 -1.845
BMI before surgery, kg/m2 51.1 (N=65) 48.6 (n=17) 52.8 (n=40) 0.084 4.223 -0.587 9.034
Waist at follow up, cm 96 (N=65) 101 (n=17) 95 (n=40) 0.070 -6.393 -13.330 0.545
Common channel, cm 71 (n=62) 72 (n=16) 69 (n=38) 0.539 -2.977 -12.639 6.685
BMI reduction, kg/m2 21.2 (N=65) 18.2 (n=17) 22.9 (n=40) 0.023 4.726 0.679 8.773
months since surgery 36.5 (N=65) 40.6 (n=17) 35.2 (n=40) 0.031 -5.438 -10.359 -0.518
Patients with a z-score below -1.0 SD were significantly older compared to those with 
a TBBD above -1.0 SD. They also tended to have a higher BMI pre-surgery however 
this was not statistically significant. Patients with a higher TBBD had a greater
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reduction in BMI (mean reduction was 23 kg/m2), than those with a low TBBD (mean 
reduction 19.6 kg/m2). Again this difference was not statistically significant.
We looked carefully at patients with a TBBD z-score below -2.5 (n=5) they had 
significantly longer time past since surgery (p= 0.000). Average time since surgery for 
those with a TBBD z-score above -2.5 SD was 35.9 (8.7 SD) months while it was 
45.8 (2.6 SD) months for those below. Waist circumference was significantly higher 
for those with a z-score below -2.5 SD group, with a mean of 107 cm compared to a 
mean waist circumeference of 95.6 cm for those with a z-score above -2.5. These 
differences were not significant between those with a z-score above or below -1.0 SD. 
Table 23. Correlation analysis of total body bone density z-scores with 
patient characteristics
Total body bone density tot group (n=57) women (n=48) Men (n=9)
coefficients p-value Coefficients p-value coefficients p-value
age, years - 0.255 0.056 - 0.176 0.232 - 0.634 0.066
months since surgery - 0.294 0.026 - 0.205 0.161 - 0.184 0.635
BMI reduction, kg/m2 0.341 0.009 0.291 0.045 0.611 0.081
waist circumference, cm - 0.507 0.000 - 0.421 0.003 - 0.703 0.035
Variables related to weight and weight change, related most significantly to bone 
mineral density. BMI reduction and BMI at follow-up were significantly correlated to 
TBBD.
Table 24 presents patient characterstics correlated with lumbar spine bone density.
Table 24. Relationship between lumbar spine bone density and patients 
characterstics
Lumbar spine bone densityL1-L4 z-score tot group (n=57) women (n=48) men (n=9)
coefficients p-value coefficients p-value coefficients p-value
age, years - 0.006 0.963 0.021 0.886 -0.577 0.104
BMI reduction, kg/m2 0.191 0.154 0.120 0.417 0.350 0.356
waist circuference, cm - 0.357 0.006 0.002 0.991 -0.650 0.058
Table 25 presents patient characteristics correlated with dual femur bone density z-
scores.
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Table 25. Relationship between dual femur z-scores and patient 
characteristics.
Dual femur bone density tot group (n=56) women, (n=48) men, (n=8)
coefficients p-value coefficients p-value coefficients p-value
age, years - 0.233 0.084 -0.085 0.564 -0.577 0.104
BMI reduction, kg/m2 0.418 0.001 0.377 0.008 0.350 0.356
waist circumference, cm - 0.308 0.021 -0.249 0.088 -0.650 0.058
Table 25 presents patient characteristics correlated with serum I-CTP.
Table 25. Relationship between serum I-CTP and patient characteristics 
Correlation analysis of C-terminal telopeptide
of type I collagen
tot group women men
coefficients p-value coefficients p-value coefficients p-value
Age, years (n=54, f=48, m=6) - 0.389 0.004 0.102 0.492 -0.890 0.001
BMI reduction, kg/m2 (n=54, f=48, m=6) 0.302 0.027 0.143 0.334 -0.049 0.894
s-calcium alb corr (n=53, f=47, m=6) 0.452 0.001 0.164 0.272 0.431 0.214
s-albumin (n=53, f=47, m=6) - 0.353 0.010 0.120 0.423 0.360 0.307
3.5.4 Regression analysis of BMD z-scores and I-CTP
The most important dependant variables including BMD and I-CTP were studied 
further to understand which of the clinical characteristics were the most important and 
statistically significant correlates. With a small population of about 50 individuals 
only about 4-5 characteristics could be included in the regression analyses.
Table 27, 28 and 29 show multiple regressions of the independent variable TBBD and 
the dependent variables BMI reduction and BMI pre-surgery controlling for age and 
common channel. 
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Table 27. Regression analysis of total body bone density z-scores
Multiple regression of total body bone density (TBBD) 
n=54 coefficient p-value 95% confidence interval
TBBD, z-score -0,264 0,825 -2,657 2,129
age, years -0,027 0,252 -0,075 0,020
BMI reduction, kg/m2 0,049 0,046 0,001 0,096
common channel, cm 0,000 0,972 -0,023 0,023
Table 28. Regression analysis of total body bone density z-scores
Multiple regression for total body bone density (TBBD)
n=54 coefficient p-value 95% confidence interval
TBBD, z-score -0.362 0.826 -3.653 2.929
age, years -0.028 0.257 -0.077 0.021
BMI pre-surgery, kg/m2 0.024 0.246 -0.017 0.066
common of channel, cm -0.001 0.934 -0.025 0.023
Table 29. Regression analysis of total body bone density z-scores
Multiple regression of total body bone density (TBBD)
  n=54 coefficient p-value 95% confidence interval
TBBD, z-score 0,795 0,645 -2,653 4,243
Age, years -0,030 0,215 -0,078 0,018
BMI reduction, kg/m2 0,078 0,068 -0,006 0,163
common channel, cm 0,000 0,978 -0,023 0,023
BMI pre-surgery, kg/m2 -0,031 0,394 -0,103 0,041
Total body bone density was positively correlated with BMI reduction controlled for 
age and common channel. This was not the case for BMI pre-surgery, but BMI 
reduction was not significantly correlated with TBBD when controlled for this 
variable. 
Table 30, 31 and 32 show multiple regressions of the independent variable lumbar 
spine bone density and the dependent variables BMI reduction and BMI pre-surgery 
controlling for age and common channel. 
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Table 30. Regression analysis of lumbar spine z-scores
Multiple regression of lumbar spine L1-L4 (AP spine) 
n=54 coefficient p-value 95% confidence interval
AP spine, z-score -2,137 0,151 -5,080 0,806
age, years 0,011 0,699 -0,047 0,070
BMI reduction, kg/m2 0,041 0,166 -0,018 0,100
common channel, cm 0,002 0,895 -0,026 0,030
Table 31. Regression analysis of lumbar spine z-scores
Multiple regression for lumbar spine bone density (AP-spine)
n=54 Coefficient p-value 95% confidence interval
AP-spine, z-score -2.435 0.225 -6.417 1.547
age, years 0.011 0.701 -0.048 0.071
BMI pre-surgery, kg/m2 0.024 0.345 -0.027 0.075
common channel, cm 0.001 0.949 -0.028 0.029
Table 32. Regression analysis of lumbar spine z-scores
Multiple regression of lumbar spine L1-L4 (AP spine)
n=54 coefficient p-value 95% confidence interval
AP spine, z-score -1,611 0,452 -5,878 2,657
agecons, years 0,010 0,736 -0,050 0,070
BMI reduction, kg/m2 0,056 0,289 -0,049 0,161
common channel, cm 0,002 0,898 -0,027 0,030
BMI pre-surgery, kg/m2 -0,015 0,731 -0,105 0,074
Lumbar spine bone density was not correlated with changes in BMI or BMI pre-
surgery when controlling for age and common channel. 
Table 33, 34 and 35 show multiple regressions of the independent variable dual femur 
bone density and the dependent variables BMI reduction and BMI pre-surgery 
controlling for age and common channel. 
Table 33. Regression analysis of dual femur z-scores
Multible regression of dual femur bone density z-scores
n=53 coefficient p-value 95% confidence interval
dual femur, z-score -0,750 0,477 -2,853 1,353
age, years -0,021 0,306 -0,062 0,020
BMI reduction, kg/m2 0,055 0,011 0,013 0,096
common channel, cm 0,000 0,969 -0,019 0,020
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Table 34. Regression analysis of dual femur z-scores
Multiple regression for Dual femur bone density
n=53 Coefficient p-value 95% confidence interval
dual femur, z-score -1.818 0.205 -4.659 1.024
age, years -0.019 0.358 -0.061 0.022
BMI pre-surgery, kg/m2 0.043 0.019 0.007 0.079
common channel, cm 0.000 0.982 -0.020 0.019
Table 35. Regression analysis of dual femur z-scores
Multible regression of dual femur bone density z-scores
n=53 coefficient p-value 95% confidence interval
dual femur, z-score -1,285 0,393 -4,283 1,712
age, years -0,020 0,346 -0,061 0,022
BMI reduction, kg/m2 0,040 0,275 -0,033 0,112
common channel, cm 0,000 0,965 -0,019 0,020
BMI pre-surgery, kg/m2 0,016 0,614 -0,046 0,077
Dual femur bone density was positively correlated with reduction in BMI and BMI 
pre-surgery when controlled for age, and common channel length, but not when
controlled for each other.  
Table 36, 37 and 38 show multiple regressions of the independent variable I-CTP and 
the dependent variables BMI reduction and BMI pre-surgery controlling for age and 
common channel. 
Table 36. Regression analysis of total serum I-CTP
Multiple regression of serum-I-CTP
n=51 coefficients p-value 95% confidence interval
I-CTP, ug/L 7,628 0,001 3,435 11,821
age, years -0,072 0,017 -0,131 -0,013
BMI reduction, kg/m2 0,087 0,006 0,026 0,147
common channel, cm -0,017 0,467 -0,062 0,029
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Table 37. Regression analysis of total serum I-CTP
Mulitple regression for serum-I-CTP
n=51 coefficient p-value 95% confidence interval
I-CTP, ug/L 7.355 0.005 2.288 12.423
age, years -0.071 0.026 -0.134 -0.009
BMI pre-surgery, kg/m2 0.051 0.071 -0.005 0.107
common channel, cm -0.024 0.305 -0.072 0.023
Table 38. Regression analysis of total serum I-CTP
Multiple regression of serum-I-CTP
n=51 coefficients p-value 95% confidence interval
I-CTP, ug/L 9,098 0,001 4,046 14,151
age, years -0,077 0,012 -0,137 -0,018
BMI reduction, kg/m2 0,139 0,021 0,022 0,256
common channel, cm -0,011 0,633 -0,058 0,035
BMI before surgery, kg/m2 -0,054 0,300 -0,157 0,049
Serum levels of I-CTP at > 2 years post surgery had a strong negative correlation with 
age. Those who had I-CTP levels above reverence range were younger with a mean 
age of 36 years compared to 42 years in the group with normal values. This 
relationship was significant when controlled for all the other variables. In addition I-
CTP levels were positively correlated with BMI reduction, but not BMI pre-surgery. 
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4. Discussion
This study confirm previous findings that there is a high incidence of increased bone 
turnover and fat soluble vitamin deficiency (vitamin A and D) after BPD-DS.1 No 
significant relationship between nutrient status and length of common channel was 
detected. Markers of bone metabolism were related to the degree of weight loss. 
Average bone mineral density was within normal range compared to the reference 
population, but 25-32 % had decreased levels and men had significantly lower BMD 
than women (p=0.02). Patients with low BMD tended to be older, have lower BMI 
pre-surgery and had a lower weight reduction. BMI reduction had the strongest 
correlation to BMD results. There was no relationship between nutrient intake and 
biochemical measurements or BMD. 
4.1 Patient characterstics
The purpose of the study was to investigate patients 2 - 5 years after BPD-DS surgery 
to gain insight into their nutrient and bone health status after they had returned to a 
stable metabolic state. Participation rate was 84 %, which included all patients who 
showed up for follow-up consultations a part from one. Patients did not attend 
consultations for several reasons. Some had too far to travel and/ or psychological 
problems, some had been transferred to other follow-up programs, some stated that 
they did not wish to have follow-up treatment and others did not respond to repeated 
attempts of being contacted. One patient was excluded due to incomplete and 
suspected inaccurate measurements in several study parameters. He was also admitted 
for correctional surgery (to lengthen his common channel) during the post-surgery 
follow-up assessments. It is likely that this patient was in an unstable metabolic state, 
and that his test results do not resemble that of a more metabolically stabilized > 2 
years post surgery patient. All these factors lead to the decision to exclude all his data.
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Gender distribution
Our study population included 85 % women and 15 % men. The uneven distribution 
between genders may be representative to the general bariatric patient population. 
One university hospital in Norway which performs such procedures informed us that 
60-70% of referred patients were women. 56 However findings related to differences 
between gender requires further investigation before any conclusion can be met.
Control group
No other group had undergone similar metabolic change and therefore we did not 
include a control group in our study. It could have been relevant to compare data from
a morbid obese population which had not undergone surgery to determine whether 
BPD-DS is more detrimental to bone health than remaining morbidly obese. Although 
studies show increased incidence of vitamin D deficiency and increased serum PTH 
levels, data on BMD in the morbidly obese population before bariatric surgery is 
limited.57, 58
4.1.1 Results anthropometric characteristics
All patients had achieved satisfactory weight loss, after > 2 years post- surgery, with 
at least 50 % of excess weight loss maintained at follow-up. The study population had 
a mean loss of 62 kg and 76 % of excess weight. Hence the average patient was no
longer classified as obese 2-5 years post-surgery. According to the WHO 
classification, these results meant that our population sample significantly reduced 
obesity associated health risk. Some patients achieved sufficient weight loss to 
achieve a normal weight (BMI 18.5-25), while some patients sustained a BMI in the 
morbidly obese category. One patient had a BMI above 45 at follow-up consultations, 
however with an initial BMI above 70, the weight loss and subsequent health benefits 
were invaluable. 
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Height measurements
Results from pre-surgery height measurements were used to determine changes in 
BMI. Although the changes in height were not significant (p=0.703), some patients 
were several centimetres shorter at follow-up, which would have underestimated their 
weight loss had the new height measurements been used in BMI calculations.
Mean and median values
We presented mean and median values because there was an uneven distribution of 
several study parameters. The large majority of this patient group weighed between 
110 and 170 kg pre surgery, but one weighed 215 kg, while one patient weighed only 
108 kg. The low value did not have the same effect on the distribution, as her weight 
did not range as far from the majority of the patient group as the extreme high value.
4.2 Bone mineral density (BMD)
DXA measurements were obtained from 88 % of the study population. Average bone 
mineral density was within normal range for the study population with a mean TBBD 
z-score of -0.31, but 25-32 % had decreased levels (less than -1.0 SD of reference 
population). (Only 7-12 % had z-scores above 1.0 SD). Mean values for the whole 
group indicated normal BMD for all three z-scores. However there was a wide range 
and only TBBD 68 % had normal values. The male group had much lower total body 
and AP spine bone density than the women, with a mean BMD below normal at -1.23 
and -1.64 SD for the two values respectively. These results indicated that BPD-DS 
has some detrimental effect on bone mineral density, although it is uncertain how 
much is attributable to BPD-DS and how much is a result of disturbances seen in 
morbid obesity. Further bone mineral density studies later than 5 years post-surgery 
may be necessary to determine whether BPD-DS decreases bone mineral density.
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Case
The lowest TBBD was measured in the male group. This man had a z-score of -3.3 
and a T-score of -2.7 SD which could qualify him, according to WHO diagnostic 
criteria, as having severe osteoporosis at the age of 59 years. Mean difference in z-
score between gender was not significant in any of the parameters measured, most 
likely due to the male group being much smaller than the female group (n=9 vs n=49 
respectively).
4.2.1 Z-score vs t-score
BMD z-score was used as opposed to t-score results because the purpose was to 
investigate BPD-DS effect on bone mineral density and it was considered more 
relevant to compare results with individuals of equal age and gender. Guidelines also 
state that z-score should be used when evaluating DXA measurements in pre-
menopausal patients, although fewer patients are diagnosed with low bone mineral 
density (osteopenia) when z-scores are used. 59 It would have been of great value if 
patients had measured BMD before surgery. This would have made it possible to gain 
some insight into how much bone mineral loss is attributable to BPD-DS as opposed 
to their previous condition as morbidly obese. 
Menopause
Menopause was not taken into account in this study and may have been relevant 
because most patients were in their forties and fifties (when menopause often
presents). The perimenapausal stage (the first five to eight years after menopause
initiates) is associated with particular increase in bone turnover and bone loss, a result 
of the large impact estrogen withdrawal has on bone. 43 This could have been an 
important confunding factor and should have been considered.
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4.3 Biochemical measurements
4.3.1 Nutrient status
The majority of our patients had normal or low serum values of all nutrients despite 
high doses of supplements. Corrected calcium and 25(OH)D levels were decreased in 
25 and 22 % respectively. The highest incidence of nutrient deficiency was vitamin A, 
which was low in 66 %. Vitamin A supplementation was recommended through a 
multivitamin and mineral supplement as well as from cod liver oil with vitamin A, D 
and E. Considering the high incidence of vitamin A deficiency and low compliance in 
taking the latter supplement, this may indicate that alternative vitamin A 
supplementation is necessary. However we found no correlation between supplement 
compliance and any of the markers of nutrient status which may indicate that the 
differences in level of malabsorption, is the most important determining factor for 
nutrient status. If this is true, a possible solution to the high incidence of vitamin D 
deficiency could be to recommend increased sun exposure to ensure that vitamin D 
needs are met. 
4.3.2 Markers of bone metabolism
Biochemical markers of bone turnover were significantly increased in a large 
proportion of the study population. Increased incidence of secondary 
hyperparathyroidism and vitamin D deficiency have also been established in the 
morbidly obese popualtion.12 The relative contribution of morbid obesity and BPD-
DS surgery to these disturbances has yet to be determined.  
Balsa et al stated that approximately 70% of patients who undergo biliopancreatic 
diversion develop secondary hyperparathyroidism in the long term. A particularly 
high incidence of increased serum-PTH levels in our study confirmed that which has 
been shown in previous studies. 25, 35 A total of 92 % had increased serum-PTH. Other 
markers of increased bone turnover, such as I-CTP was raised in 45 %, and 28 % had 
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increased active vitamin D levels (calcitriol). Bone specific-ALP, a marker of bone 
formation, was also raised in 69 %, but osteocalcin was normal in all but one patient. 
The high incidence of increased bone turnover and resorption markers was an 
indication of abnormal rates of bone resorption. These results confirm previous 
findings that there is a high incidence of increased bone turnover after BPD-DS. 28, 60
Considering that BMD results appeared to be less affected by the apparent increased 
bone turnover than expected, further study is necessary to determine whether it will 
affect BMD in the longer term. There is a lot of uncertainty around the long term 
effects of increased PTH and bone turnover after bariatric surgery. Studies 
persistently show a high incidence of secondary hyperparathyroidism, but long term 
data has not yet shown expected effects on BMD. The morbid obese population have 
decreased vitamin D and increased PTH levels, a result of increased uptake and 
clearance of 25(OH)D by adipose tissue. 29 One question is whether the increased 
food intake that happens over time after BPD-DS combined with less adiposity and 
subsequent increased bioavailability of vitamin D, will moderate PTH levels later on 
and prevent long term effects on BMD.60
4.4 Dietary intake
4.4.1 Dietary records
Great difficulty was experienced in having the 7 day pre-coded food diaries returned. 
A prospective pre-coded food diary which was quite easy, but required a little time 
each day to complete, was chosen in order to obtain as accurate information about 
nutrient intake as possible. This was considered necessary to detect any relationship 
between dietary habits with bone health parameters, but seven days of filling out this 
diary proved to be too demanding for the majority of our patients. This was despite 
thorough explanation, both written and verbal, about the food diary and providing 
patients with an addressed, pre-paid envelope in which to return the diary. As a result, 
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dietary records were obtained from 45 % of the study population.  No patient 
expressed hesitation when they were asked to complete this assessment.
Considering that there was a wide variety in patient compliance, data on less than half 
of the study population may, for example, not include those who were less compliant 
to dietary recommendations, which could have resulted in a misrepresentation of 
dietary habits. 
Alternative methods of dietary analysis
In retrospect, we could have obtained dietary information from more cases if we had 
used a less demanding dietary analysis tool. A food frequency questionnaire filled out 
on the day of consultation, perhaps together with a student clinical nutritionist, might 
have obtained the best response.  However patients were asked to fill out a number of 
forms on the consultation day and therefore this may not have been the case. Another 
alternative would have been to conduct several 24-hour recall interviews over the 
telephone. These methods however would have relied on memory, and estimation of 
nutrient intake would probably not have been as accurate. Short food questionnaires 
are not able to provide data on individual nutrients, and are better use in estimating 
food choice such as dairy products and vegetables etc. 61 For the purpose of detailed 
dietary analysis in the future, the same pre-coded food diary could be used, but the 
amount of days expected to record intake could be limited to four days.   
Limitations in assessing nutrient intake.
Other studies have shown that there are many weaknesses in available methods for 
dietary analysis. Filling out a dietary record may in it self affect intake, as patients 
tend to become more aware of what they eat when they have to write it down. 
Underreporting is common in all methods of dietary analysis, especially in the obese 
population. 62 Diet records suffer from errors in estimating portion size, from 
variability in food composition and from inadequacies of existing food composition 
tables. In addition, a snap shot of one week can not represent all intake. 61
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In this study patients recorded dietary intake after consultations with a student clinical 
nutritionist where they had received thorough dietary assessment followed by 
appropriate guidelines and recommendations for future intake. This may have 
significantly affected the recordings and must also be considered an important 
weakness in the dietary assessments. In contrast, results on mean intake of calcium
and vitamin D from dietary registrations of supplement intake showed small 
differences when compared to those from the subjective interview. This may indicate 
a greater accuracy than anticipated within these results.
Nutrient deficiency and compliance to dietary recommendations.
There was a high incidence of nutrient deficiency and non-compliance to diet and 
post-surgery supplement recommendations in our patient group, but this varied greatly 
between individuals. Negative experiences in the initial post-operative period may 
influence compliance to supplement intake in the long term. General nutrient status 
and adverse reactions to foods may also determine a patients’ willingness to comply. 
It may be beneficial to start supplementation in the pre-operative period. This could 
prepare patients for the use of supplements under normal conditions without the 
bowel discomforts and nausea often experienced in the early post-operative period. 
This could also correct any pre-surgery nutrient deficiencies and may help determine 
if the patient is in fact willing to comply with supplement recommendations post-
surgery. Williams et al recommended starting a multivitamin with minerals and a 
calcium with vitamin D supplement from the first preoperative visit.28
Energy and macronutrient intake
Results show great variations in energy intake and one patient had an average energy 
intake which was over 6400 kJ higher than any of the others (23629 kJ per day). This 
particular case should have been investigated further. The extreme recorded energy 
intake may have been wrong due to a misunderstanding during dietary recording, but 
it may also have been accurate and a result of severe malabsorption, but this was 
never clarified. 
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Energy contribution from fatty acids was particularly high with a saturated fat intake 
contributing to 16.3 % of energy intake. Fat intake was well above the governmental 
recommendations and may have been an important contributing factor to the extreme 
frequency of stéatorrhea frequently experienced in this patient group. Some reported 
up to 20 toilet visits per day. 
Important dietary recommendations in BPD-DS patients include ensuring a high 
intake of good quality protein. Our data illustrate an average protein intake of 16.7%, 
which is adequate for the general population, but is probably insufficient after BPD-
DS because of the need to compensate for malabsorption. Carbohydrate intake was 
lower than that advised for the general population, but expected for our patient group 
to allow for more protein rich foods. It should be noted however, that one quarter of 
CHO intake was provided from added sugar, and even though this contributed no 
more than recommended limits for the general population it may indicate a high 
intake of CHO sources low in micronutrients. This combined with a high saturated fat 
intake may give cause for concern about the quality of the diet in this patient group, in 
terms of providing adequate amounts of essential nutrients. 
Malabsorption
Fat malabsorption may lead to insufficient uptake of essential fatty acids and fat 
soluble vitamin deficiencies. This may have severe clinical consequences and can 
alter calcium metabolism. Previous studies have shown a progressive increase in the 
incidence and severity of hypovitaminemia A, D and K with time after BPD-DS. 15, 63
This may affect calcium metabolism and increase the incidence of secondary 
hyperparathyroidism.10 This should also be considered in relation to the uncertain 
effectiveness of absorption from supplements.
Micronutrient intake
The dietary analysis software KBS, did not include functions for analysing folate, B12 
and vitamin K, so dietary intake of these nutrients could not be estimated. Average 
intake of the other micronutrients mostly met the Norwegian governments (Sosial- og 
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helsedirektoratet) Recommended Dietary Intake (RDI)64, apart from vitamin D intake 
which was only 6 µg per day on average. Considering the large malabsorption 
characterised in this patient group however, the net absorbed micronutrients from 
food intake is likely to be insufficient. Micronutrient intake also varied greatly 
between individuals, which again illustrates the profound variation in the quality of 
our patients’ diets. 
Food contribution to nutrient intake
Several patients had become intolerant to dairy products after the BPD-DS procedure 
and this has also been shown elsewhere 14. Dairy products were, however, were still 
the most important source of calcium, and patients often reported using these products 
despite symptoms of lactose intolerance. Fruit and vegetables appeared to contribute 
less to Mg and vitamin A (in the form of β-carotene) than could be expected, 
illustrating a low intake of these food groups. 
Important sources of vitamin A, such as meat and meat products and dietary fats, were
frequently consumed. According to biochemical measurements this did not ensure 
adequate supply for a large proportion of our patients. 
The Framingham heart study found that high intakes of fruit, vegetables, magnesium 
and potassium had a greater BMD in hip and forearm.65 The protective effects of fruit 
and vegetables on bone health, mediated through vitamin C and other antioxidants, 
their content of vitamin K, magnesium, potassium, zinc and fibre as well as their 
alkaline ash may also be important reasons to ensure adequate intakes in BPD-DS 
patients. 43 A high intake of this food group will also be beneficial for the 
maintenance of long-term weight loss.
Supplement intake
Several studies have emphasized the risk of metabolic bone disease in bariatric 
surgery patients if adequate calcium and vitamin D supplementation is not given. 34, 36, 
66
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Most patients took some kind of supplement. Reasons for not taking supplements 
included difficulties in swallowing the tablets, feeling of nausea or general stomach 
upsets associated with intake. Many struggled with taking the large chewable calcium 
supplements. In addition, iron supplements were often associated with cramps and 
disturbed bowel habits. Some patients took B12 injections regularly, but most had 
normal serum values despite only obtaining this vitamin from dietary sources and the 
multivitamin- and mineral supplement. 
It was difficult to obtain accurate information about the content of multivitamins and 
iron tablets due to great variations in brand choice, from known and unknown 
companies. Dietary registrations often did not disclose type of brand and / or number 
of tablets tablets taken per day. Some stated that they used some supplements from 
abroad but could not recall brand name or content. Nycomed Pharma, Nycoplus Multi 
was assumed brand were no other information was given. 
Studies evaluating the effectiveness of aggressive high-dose vitamin D 
supplementation in preventing secondary hyperparathyroidism in this patient group 
are lacking. Good compliance in high-dose vitamin D supplementation resulted in 
77% having vitamin D intake above the safe upper limit in our patient group. Despite 
this fact, no patient presented with high values and 22 % still had low serum levels, 
and other studies have found a higher incidence of vitamin D deficiencies.67
4.5 Associated links
The BPD-DS is a modification of BPD aimed at limiting consequences of 
malabsorption. But several biochemical measurements of nutrient status and bone 
metabolism were abnormal in this study.
I-CTP and changes in weight
C-terminal telopeptide of type I collagen (I-CTP) is known to correlate well with bone 
resorption rates in metabolic bone disease. 46 This biochemical marker was chosen to 
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investigate further for this reason. Biochemical markers may be better indicators of 
effects on bone metabolism in the shorter term as changes are seen more rapidly than 
in BMD. I-CTP levels were positively correlated with BMI reduction, but not BMI 
pre-surgery. This indicated an important relationship between the high rate of weight 
loss, charactersitic in BPD-DS, and effects on BMD. 
Bone mineral density compared to weight loss
Weight reduction in the obese is associated with loss of bone. The amount of bone 
loss relative to the degree of weight loss seems to vary among populations and there is 
a strong positive correlation between rate of weight loss and effect on bone density. 28
This association is important in BPD-DS because both the rate and degree of weight 
loss is high. In this study, the strongest correlation to bone mineral density was level 
of BMI reduction. One study suggested that the weight loss induced in BPD-DS is 
associated with a significant loss of bone mass even at sites that are not affected by 
weight overload. 68    
Study results indicated that those who lost the most weight post surgery had the 
highest bone density. Considering that there was a significant positive correlation 
between BMI pre-surgery and reduction in BMI, this may indicate that those with the 
highest pre-surgery BMI had the highest bone density, but this difference was not 
significant and is contrary to previous studies which have found that morbid obesity is 
detrimental to bone density. 63 The inverse relationship between waist circumference 
and TBBD may have been confounded by gender, as men tend to have a greater waist 
circumference, and they had significantly lower bone density compared to women. 
However there was also a significant relationship between waist circumference and 
TBBD in the female group.
Bone mineral density compared to supplement intake.
We found no significant difference in any of the bone mineral density z-scores 
between those who had an adequate intake of supplements and those who did not. 
BMD was compared to calcium, vitamin D and general supplement intake using an 
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independent samples t-test. Adequate intake was classified according to guidelines for 
supplement intake in this patient group. Patients were considered to have an adequate 
supplement intake if they complied with the minimum recommended intake of at least 
4000 mg of calcium (4 tablets of calcigran forte), 750 µg vitamin D (one AfiD2 forte) 
and one vitamin-mineral supplement (Nycoplus multi or equivalent) per day. Other 
supplement intake was not considered in relation to bone mineral density in this 
report. 
Nutrient intake compared to BMD and biochemical markers of bone metabolism.
We found no relationship between nutrient intake and BMD or biochemical markers 
of bone metabolism. Several factors may have affected these results. Most 
importantly, we only obtained dietary registration from 45 % of the study population 
and, as discussed, tools used in estimating nutrient intake have several limitations. 
However, we also did not detect any relationship between supplement compliance and 
nutrient status (which was available for all participants) to BMD. This could indicate 
that absorption of supplement derived nutrients may be even poorer than initially 
anticipated, however considering that supplement compliance was self-reported the 
reliability of this data may be poor. 
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5. Conclusion
Our results confirm previous findings that there is a high incidence of increased bone 
turnover and fat soluble vitamin deficiency after BPD-DS. We did not find any 
significant relationship between nutrient status and length of common channel, but 
markers of bone metabolism were related to degree of weight loss.    
Average bone mineral density was within normal range for the study population, but 
there was a high incidence of low BMD (25-30 %) and men had significantly lower 
BMD than women. These results indicated that BPD-DS has some detrimental effect 
on bone mineral density, although it is uncertain how much is attributable to BPD-DS 
and how much a consequence of disturbances as a result of morbid obesity. 
Biochemical markers of bone turnover were significantly increased in a large 
proportion of the study population.This indicated that there may be marked alterations 
in bone metabolism after BPD-DS. The relative contribution of morbid obesity and 
BPD-DS surgery to these disturbances has yet to be determined.  
Associated links
All patients had achieved satisfactory weight loss after > 2 years post- surgery. Those 
with low BMD tended to be older, have lower BMI pre-surgery and had lost less 
weight after the surgery. Greater reduction in BMI was associated with higher level of 
I-CTP. This marker of bone resorption indicated that the high rate of weight loss post-
surgery increases bone turnover. Although our results showed moderate effect on 
BMD at 2-5 years post-surgery, the significant high rates of bone turnover may affect 
BMD in the longer term. Further studies are needed to clarify this relationship.  
We found no relationship between nutrient intake and BMD or biochemical markers 
of bone metabolism. We also did not detect any relationship between supplement 
compliance to BMD. Due to the nature of nutritional effects on bone health, 
nutritional monitoring over a longer time period, and for several years post-surgery, 
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may be necessary to detect any relationship. Our data is not sufficient to accept the H0
hypothesis that nutrient intake after BPD-DS does not affect bone health. Previous 
studies have shown a clear relationship between nutrient status and bone metabolism
and we continue to emphasize the importance of ensuring patient compliance to post-
surgery nutritional recommendations and follow-up procedures. 
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Appendix 1
6.1 Bone health
6.1.1 Physiology of bone metabolism – a brief overview
Bone tissue consists of a mineral component and an organic component, and has a 
mechanical as well as a biochemical function. Calcium, phosphate and magnesium are 
the most important minerals in bone tissue. An adult skeleton consist of calcium 
bound to phosphate in the complex crystalline material hydroxyapatite which is laid 
down on an organic matrix primarily made up of collagen. The skeleton contains 
more than half of the body’s collagen, mainly in the form of type 1 fibrillar collagens. 
These extra-cellular proteins have a three-dimensional overlap structure called quarter 
stagger array, which provides gaps or hole zones where mineralization occurs. Bone 
metabolism maintains adequate levels of calcium for physiological processes in the 
body. The organic matrix also contains non-collagen proteins classified into 
sialoproteins (containing γ-carboxyglutamic acid (Gla proteins)), phosphoproteins 
(osteonectin) and bone proteoglycans.48, 46 chapt 3, page 17-26
Bone formation and resorption 
The turnover of bone is controlled by the activities of osteoblasts, osteoclasts, and 
osteocytes influenced by mechanical, nutritional and hormonal factors. Only a 
fraction of bone cells are active at a time. Remodelling ensures bone tissue vitality 
and elasticity. The synthesis, deposition and mineralization of the organic matrix 
involves expression of a number of genes by the osteoblasts. Production of type I 
collagen takes place during the proliferation of osteoblast precursor cells. After 
cessation of cell proliferation the expression of alkaline phosphatase starts. 
Osteocalcin is a calcium-binding protein expressed during matrix mineralization.47
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Osteoblasts
Osteoblasts are differentiated from osteoprogenitor cells located in the periosteum and
the bone marrow. Osteoblasts control bone turnover and are responsible for bone 
formation. They respond to endocrine, nutritional and mechanical signals released by 
osteoclasts and osteocytes.  Communication of osteoclasts and osteoblasts is achieved 
through cytokine signaling. The signaling pathways are regulated by several 
hormones such as parathyroid hormone (PTH), vitamin D, growth hormone, steroids 
and calcitonin. Osteoblasts have receptors for PTH, 1.25(OH)2D3, estrogen, and 
prostaglandin E2. Remodellation and metabolic activity is far greater in trabecullar 
bone than in corticalis, and has a larger surface area.48
Osteoclasts
After activation and stripping of bone collagen, osteoclasts will start bone resorption. 
Osteoclasts derive from the fusion of cells of the monocyte-macrophage cell line. 
They are large and characterized by multiple nuclei, a homogenous, foamy cytoplasm 
and high concentration of vesicles and vacuoles. Osteoclasts dissolve bone mineral 
and release lysosymal enzymes, such as tatrate resistant acid phosphatase and proteins 
which create an acidic environment which break down the organic matrix.47
When the resorption process is finished, the bone formation cells (osteoblasts) start 
depositing osteoid composed mainly of type I collagen. Osteoid is mineralized into 
osteoid matrix under the influence of vitamin D and osteocalcin. Provided there is 
pre-existing bone surface after resorption, it will always be followed by a formation 
phase. As implied this will not be possible if the resorption process has resulted in a 
breakthrough (perforation) of the trabechular bone.69
Determinants of bone mineral density (BMD)
Bone mineral density is dependent on peak bone mass and subsequent bone loss.44
Bone mass is steadily increasing in early stages of life until it reaches its’ peak 
between 20 and 30 years of age. Total body bone mass remains relatively constant 
through reproductive years, then age-related bone loss occurs, which varies between 
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individuals, but occurs most rapidly during the first three years after menopause in 
women (perimenapausal stage). Average adult bone loss is 1% per year. Age related 
decreases in calcium absorption and increases in urinary calcium excretion contribute 
to this loss. Some women will lose up to 6 % per year in the perimenapausal stage. 
Because women generally have a lower peak bone mass, the development of 
osteoporosis is seen most frequently in women. The explanation for bone loss during 
aging includes declining calcium intakes, declining physical activity, decreased levels 
of gonadal hormones, decreased levels of circulating calcitriol, and intestinal 
resistance to this hormone.43, 28
Genetic predeterminants of peak bone mass account for 60 – 80 %. Environmental 
determinants of BMD include nutritional intake, smoking, excessive alcohol intake 
and starvation (anorexia) which may decrease bone mass. Peak bone mass is 
approximately 25 % less in females compared to males, but there are great individual 
variations. Adequate diet and weight bearing exercise is important to ensure potential 
peak bone mass is achieved. Immobilization, tobacco and alcohol increases bone 
mineral loss, as does early onset menopause which is related to a fall in oestrogen 
levels.46, 70
Dietary determinants of bone mineral density
Nutrition is one of the important modifiable risk factors in the development and 
maintenance of bone mass and the prevention and treatment of osteoporosis. Calcium
and phosphorous compose about 80-90 % of bone mineral content. Protein is part of 
the organic matrix collagen structure where mineralization takes place and several 
other vitamins and minerals also play vital roles in bone metabolism.43
Energy and protein
Body weight is positively correlated with BMD. This may be due to greater weight 
bearing stress on the skeleton which stimulates bone formation. Weight loss is 
associated with bone loss. A 10 % weight loss typically results in 1 – 2 % bone loss.58, 
43 Severe weight loss and malnutrition is therefore considered important risk factors 
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for osteoporosis. This may be due to subsequent low protein intake, low general 
micronutrient intake including those necessary for healthy bone metabolism, muscle 
weakness which increases the risk of falling, and less padding to protect the skeleton 
during falls.43
Protein intake is associated with urinary excretion of calcium. The higher the protein 
intake the more calcium is lost. This is mainly due to the acid load of the sulphate 
produced in the metabolism of sulphur containing amino acids. A high protein diet 
may therefore be detrimental to bone health. However protein rich foods typically also 
contain phosphorous, which has a hypocalciuric effect and may inhibit the 
hypercalciuric effect of the protein. The link between high protein intake, calciuria 
and risk of osteoporosis is prevented when adequate calcium intake is ensured. There 
is also evidence that a protein deficient diet may reduce bone density due to 
subsequent reduced calcium absorption and IGF-1 levels.43 Studies have found higher 
levels of bone resorption markers in diets with a lower protein intake compared to 
diets with a higher protein intake.71
Acid- Alkaline Ash
The skeleton may provide ion exchange as a buffer system to neutralize acid or 
alkaline disturbances after food intake. Some foods may produce and acid ash, for 
example meat, while fruit and vegetables have an alkaline ash and dairy products 
have a neutral ash. One hypothesis is that metabolic acidosis following a meal may 
cause increased bone resorption in order to release calcium ions and neutralize low 
pH. High intakes of meat could for example cause depletion in calcium stores and 
increase the risk of bone disease.43
Caffeine
Caffeine is believed to impair intestinal calcium absorption, but studies are 
inconclusive as to its effect on bone health. Its’ negative effect is only relevant when 
calcium intakes are low.43
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Calcium
The adult human body contains approximately 1000-1250 grams of calcium 
(depending on body size, gender and race) and 99 % is bound up in skeletal tissue. 
Free calcium is present in extra-cellular fluid, in all cells of the body and in the 
circulation as an easily exchangeable pool of calcium electrolytes.39
Calcium has both a structural role in the body as an important component of bone 
mass, and a mechanical role. The regulation of calcium metabolism is primarily 
concerned with protecting its’ mechanical role which is vital in muscular, 
neurological and endocrine systems within the body. Free calcium plays a key role in 
signal transduction within and between cells, in neuromuscular transmission, in 
glandular excretion and in enzymatic reactions. Ionized calcium is the most common 
signal transduction element in cells, because of its ability to reversibly bind to 
proteins. These processes are dependent on a constant supply of calcium ions which is 
provided by the circulation.39
Calcium balance is maintained by several mechanisms including gut absorption, bone 
resorption and renal reabsorption.28 This exchange is controlled by calciotrophic 
hormones, such as PTH, 1.25(OH)2vitD3 (calcitriol) and calcitonin (but also locally 
acting hormones including cytokines).48
Absorption
Vitamin D status, intestinal transit time and mucosal mass affect calcium absorption.   
Dietary calcium is combined with calcium from the digestive juices in the small 
intestine. Active calcium uptake occurs in the duodenum and, when there is increased 
physiologic need, also in the ileum and to a small extent the jejunum and colon. 
Passive calcium absorption appears to occur across the lining the whole length of the 
intestine.46 chapt 21, page 104-107. The active calcium absorption process is 
dependent on vitamin D. The difference between ingested calcium and that excreted 
in the faeces is termed net absorption. Net absorption fraction increases with 
decreased intake and with increased physiological needs. This adaptation is dependent 
on sufficient vitamin D being present and may become less efficient with increasing 
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age. In normal healthy individuals, 20-60 % of dietary calcium is absorbed.39, 46, 72  
Calcium absorption is inefficient in compensating for a fall in calcium intake. 
Absorption from the colon accounts for about 5 % of total absorption in normal 
individuals but may be important in patients with small bowel resections and where 
colonic bacteria break down dietary complexes. Decreased stomach acid reduces the 
solubility of insoluble calcium salts and reduces absorption unless fed with a meal.  
The calcium from most supplements is absorbed as well as that from milk. Absorption 
of one very soluble salt, calcium-citrate, may be better than that of other salts because 
citrate appears to enhance paracellular calcium transport. Absorption of calcium 
supplements improves when they are taken with food, perhaps by slowing gastric 
emptying and extending time in which the calcium containing chyme is in contact 
with the absorptive surface.46 chapt 21, page 104-107.
Calcium absorption may be inhibited by the presence of phytic acid, oxalic acid or 
phosphates. This interaction may become significant when calcium intake is low and/ 
or when there is a high intake of fibre rich foods.39 There is some concern related to 
the intake of high phosphate containing drinks (such as coffee and dark coloured soft 
drinks) Elevated PTH levels, if sustained, could lead to bone resorption, but this 
effect has been reported in both diets with elevated phosphorous and low calcium 
levels. Low calcium levels alone may account for observed elevation in PTH. 
Assessing calcium status
Calcium metabolism is in equilibrium with plasma calcium concentrations of about 
2.1-2.60 mmol/L. Serum calcium level is regulated by calciotrophic hormones, and 
varies very little (1-2%). Total serum-calcium is a reliable analysis under normal 
conditions, but should also be corrected for serum-albumin. Serum calcium levels are 
rarely low as a result of low dietary intakes. Low serum Ca2+ may imply an 
abnormality of parathyroid function. Plasma calcium concentration rises in response 
to: increased calcium absorption; increased tubular reabsorption; and bone resorption. 
When this happens, the renal excretory threshold changes and extra calcium is 
excreted in the urine. Measuring urinary calcium in a 24-hour sample can be useful in 
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assessing adequate calcium intake. Abnormal low urine content where there is normal 
renal function suggests inadequate intake and/ or absorption.
If dietary supply is insufficient, calcium is released from bone tissue to maintain 
normal circulating levels. Hence normal s-calcium levels do not guarantee that there 
is adequate supply of calcium.28 Plasma calcium concentrations may be abnormal for 
a number of reasons. Hypercalcaemia may be seen in diseases such as: malignant 
disease; primary hyperparathyroidism; granulomas; vitamin D overdosage; milk alkali 
syndrome; immobilization; thyrotoxicosis; hypercalcaemia of infancy; familial 
hypocalciuric hypercalcaemia. Hypocalcaemia may be seen in vitamin D deficiency 
(and disturbances in its metabolism); hypoparathyroidism and 
pseudohypoparathyroidism. Adequate calcium intake protects against osteoporosis 
and has been associated with reducing the risk of hypertension, colon cancer, lead 
poisoning and kidney stones in patients with short bowel syndrome.46
Recommended dietary calcium intake for healthy Norwegian adults is 800-900 mg per 
day.39 Calcium requirements is the amount of dietary calcium required to replace 
losses in the urine, faeces and sweat plus the calcium needed for bone accretion 
during periods of skeletal growth. The recommended dietary intake for calcium is 
based on skeletal needs. The calcium intake required by older adults to achieve mean 
maximal retention or minimal loss was determined to be 1200 mg/day. This is also 
sufficient to protect against risk of hypertension. Bone metabolism responds to 
calcium intake up to a certain threshold when calcium needs are met, after this 
additional calcium supply will not improve bone mass. Ilich and Kersttner estimated 
that variations in calcium intake during early stages of life may account for 5 to 10 % 
of the difference in peak bone mass. This impact could contribute to more than 50 % 
of hip fracture rates later in life.43 Supplementation is recommended when adequate 
intake is not met.44
Calcium intake up to 2.5 grams per day is considered safe. Higher intake is difficult to 
achieve through diet alone, but may be obtained through supplementation and can 
lead to hypercalcaemia if there is also a high intake of vitamin D.39
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Phosphorous
Phosphorous is widespread throughout the body which contains 800-1200 g, 85 % is 
contained in the hydroxyapatite complex of bone. Hydroxyapatite contains calcium 
and phosphorous in the ratio of 1:2. In soft tissue phosphorous is mainly bound to 
organic compounds. Phosphorous plays a role in biochemical reactions involving 
organic phosphates such as adenosine tri-phosphate, and it is an integral part of 
phospholipids, phosphoproteins and phosphosugars.39, 48 Phosphate is absorbed by 
several mechanisms mostly as inorganic phosphate achieved through hydrolysation of 
dietary organic compounds. Absorption of heavily soluble compounds such as phytate 
is believed to be low.39
Plasma phosphorous concentrations are relatively constant at 0.8-1.4 mmol/L and its 
balance is regulated by the amount reabsorbed in the kidneys. Vitamin D status affects 
the absorption of phosphate. Increased availability of calcitriol increases its 
absorption and decreased calcitriol has the opposite effect.39 PTH reduces the renal 
reabsorption, calcitonin also increases phosphate excretion by the kidney. 
Excessive phosphate consumption may be detrimental to bone. A rise in phosphate 
intake leads to a rise in serum concentrations which leads to reduced ionized calcium 
and increased PTH content in blood. A high phosphate – low calcium diet may cause 
hypocalcaemia or secondary hyperparathyroidism. Of particular concern is the 
phosphate content of carbonated beverages, which causes a high acid load from the 
phosphoric acid used as acidulant, and its frequent consumption in our population 
especially the younger generations. The tendency of these drinks to replace milk in 
the diet may further exacerbate their effect on bone health.43
Phosphorous deficiency (which may occur with prolonged use of aluminium-
containing antacids) has widespread effects and there are important bone diseases 
related to phosphorous metabolism. Phosphate deficiency may cause osteomalacia, 
myopathy, growth failure and defects in leukocyte function. There is a difference 
between total body phosphorous deficiency, retention of phosphorous and its 
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redistribution between bone and soft tissue. Symptoms of phosphate deficiency 
include muscle weakness, lack of appetite, nausea and decalcification of bone.39
Recommendations
The Norwegian recommendations for phosphate intake is 600 mg per day for adults. 
64 Phosphorous is present in all food groups and is often related to protein content.
Magnesium
Magnesium content in the body is approximately 25 grams. The skeleton contains 60
% and the remainder is distributed in soft tissue.43 Magnesium is an important co-
factor in the PTH-receptor complex. Plasma magnesium is kept constant by a rapid 
adaptation of the kidneys. Total plasma magnesium is 1.7-2.3 mg per 100 ml. 
Magnesium plays an important role in calcium and bone metabolism. It affects bone 
remodelling and strength and appears to have a positive correlation with hip bone 
mineral density.28  
Recommended daily intake of magnesium is 350 and 280 mg for women and men 
respectively. 73 Net intestinal magnesium absorption appears to be linearly related to 
intake (like phosphorous), but at very low intakes a negative magnesium balance can 
occur. It is increased by both vitamin D and PTH. The tissues will only lose 
significant levels of magnesium if the intake is very low over a prolonged period of 
time or if intestinal losses are high. Hypomagnesaemia occurs in association with 
hypocalcaemia but may also be found on its own. The most common cause of 
magnesium deficiency is probably malabsorption, especially where this results from 
small bowel resection. Other causes include: dietary deficiency from protein energy 
malnutrition and prolonged parenteral nutrition; excessive renal loss, diabetes, in 
which there is both an increase in the renal loss and increased transport of magnesium 
(as well as potassium) into the soft tissues when insulin is given. Magnesium 
deficiency must be severe to impair calcium absorption. Chronic hypomagnesaemia 
impairs PTH secretion, resulting in altered calcium metabolism, hypocalcaemia and 
vitamin D abnormalities, This further decreases jejunal magnesium absorption.38, 43
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Biochemical indicators of magnesium deficiency may be characterised by a tendency 
of higher serum-calcium and lower serum-phosphate. Magnesium deficiency 
decreases bone strength and volume, impairs bone development and leads to the 
uncoupling of bone formation and resorption. 43
There is no relationship between magnesium and calcium absorption under normal 
magnesium levels.74 Studies on magnesium supplementation after bariatric surgery 
are lacking.28
Fluoride
Fluoride is present in very small amounts in food and water. It is easily absorbed by 
passive diffusion in the intestines and is incorporated into teeth and bone.43
Incorporation of fluoride into bone increases the size of the apatite crystals and hence 
decreases their solubility. In addition fluoride seems to stimulate osteoblast activity, 
increase bone formation and has shown a general increase of spinal bone mass of 5 to 
10 %.43
Iron
Iron may act as a cofactor for enzymes involved in collagen synthesis. Ilich and 
Kerstetter examined the relationship between bone mass and ferritin in a four year 
clinical trial in adolescent girls. They found a positive association between ferritin 
levels and BMD, but concluded that further studies are needed to establish this 
connection. Iron may also act as a toxin to bone cells and contribute to bone disease if 
iron metabolism is impaired or there is iron overload. It is not clear whether the 
detrimental effect on bone is a direct result of iron compounds or if it is a result of 
iron overload-induced hypovitaminosis C or both.43
Iron absorption is inhibited by other minerals and trace elements including calcium. 
This becomes particularly relevant when high doses of calcium supplementation is 
administered due to impaired nutrient absorption.43
104
Both Norkost and Ungkost showed that iron intake was lower than recommended 
among fertile women in the Norwegian population.52
Zinc
The body contains approximately one to two grams of which 90 % is found in muscle, 
bone, skin and hair. Zinc plays an important role in the metabolism of connective 
tissue, where it acts as a co-factor for enzymes such as alkaline phosphatase and 
collagenase, which enable bone mineralization and development of collagen 
structures in bone tissue.43
Zinc deficiency affects DNA synthesis and protein metabolism, this may impair bone 
formation, growth and epiphyseal formation. Zinc deficiency is associated with 
osteoporosis.43 Phytic acid, dietary fiber, calcium and low protein intake may inhibit 
absorption.43 Recommended dietary intake of iron is 9 mg for men, and 15 mg for 
women until menopause, after which requirements are similar to that of men.64
Copper
The body contains approximately 75 to 100 mg of copper. Copper deficiency is 
uncommon because it is readily available in most foods. Recommended intake of 
copper for adults is 0.9 mg per day.64 Copper plays a role in collagen maturation, and 
thus could influence bone composition and structure. 43
Sodium
Dietary sodium increases urinary calcium excretion. Because urinary calcium 
excretion account for 50 % of the variability in calcium retention, dietary sodium has 
a potentially big influence on bone loss. In adult women, each extra gram of sodium 
per day may produce an additional rate of bone loss of 1 % per year if the calcium 
loss in the urine comes from the skeleton. Animal studies have shown that salt causes 
bone loss, but there are few studies on its’ effect on bone mass in humans. 43 The 
association between sodium and calcium loss is of particular relevance when 
considering the current trend in the Norwegian population, in which there are 
decreasing calcium intakes while sodium intake remains persistently high.75
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Vitamin D
Calciferol or vitamin D, is photosynthesised in the skin of vertebrates by ultraviolet B 
radiation (UVB). The two most important forms are ergocalciferol (vitamin D2) and 
cholecalciferol (vitamin D3). Vitamin D requires two obligate hydroxylations to 
become biologically active as the hormone 1.25(OH)2D3 (calcitriol). 
76 The activation 
process requires a cytochrome enzyme system similar to the P450 system in the liver 
and 25(OH)D-1α-hydroxylase in the kidney. The production of the active metabolite 
in the kidney is carefully regulated mainly by PTH in response to serum calcium and 
phosphorous levels.76 PTH and calcitriol act synergistically to enhance renal tubular 
reabsorption of calcium and to mobilize calcium stores from bone. 
Calcitriol maintains normal serum concentrations of calcium and phosphorous by 
ensuring efficient absorption of these minerals from the small intestine.76 In the 
intestine, calcitriol stimulates the synthesis of calbindin (calcium binding protein).43
Non-calciotrophic effects of calcitriol include effect on cell differentiation and the 
immune system. Calcitriol stimulates osteoblast activity, and among other things 
increases the synthesis of osteocalcin, which effects bone mineralization. It also has a 
direct effect on the mineralization of newly formed osteoid-tissue. Vitamin D 
deficiency hence leads to insufficient mineralization of osteoid-tissue (rakitt, 
osteomalacia). Calcitriol also stimulates differentiation of resorptive cells 
(osteoclasts). 
Sources
Latitude, time of day and season has profound effects on UVB exposure, and dietary 
intake of vitamin D is clinically important because UVB exposion is often insufficient 
in northern latitudes. In the far northern countries such as Norway, there is very little 
vitamin D synthesis in the skin for up to six months of the year.76
Recommended dietary intake of vitamin D for the adult population is 7.5 µg per day, 
and 10 µg per day for persons older than 61 years. Both cholecalciferol and 
ergocalciferol are fat-soluble vitamins, which are absorbed in the entire length of the 
small bowel. Bile acids are necessary for absorption.  
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Vitamin D deficiency
Any disturbance of vitamin D production in the skin, absorption from the intestine or 
the conversion into its active form will lead to a deficient state. Disturbances in the 
calcitriol receptor may also cause deficiency, metabolic bone disease, and other 
biochemical abnormalities. 76 Vitamin D deficiency is characterized by inadequate 
mineralization or increased demineralization of the skeleton. In children this results in 
rickets, which is characterised by widening at the end of the long bones, rachitic 
rosary and deformations in the skeleton. In adults, prolonged vitamin D deficiency 
and secondary hyperparathyroidism can lead to osteopenia, osteoporosis and 
eventually osteomalacia.66
Vitamin D deficiency decreases serum concentrations of ionized calcium, which in 
turn leads to increased PTH levels stimulating calcium release from bone, reduced 
renal losses and increased excretion of phosphorous. This causes normal levels of 
serum calcium and low or low-normal serum phosphorous. Thus vitamin D deficiency 
is characterized either by normal or low-normal serum calcium with a low-normal or 
low serum phosphorous and increased PTH levels. Serum alkaline phosphatase (ALP) 
is usually also elevated. 
The elderly are at risk of developing vitamin D deficiency. Decreased exposure to 
sunlight, decreased activation of vitamin D precursors in skin, reduced ability to 
hydroxylate vitamin D into the active form in the liver and kidneys, reduced end-
organ response to calcitriol, reduced dietary intake and absorption of the vitamin may 
all be contributing factors. In addition, anticonvulsant and/ or steroid drug therapy 
impairs vitamin D status. 43 76 Patients with impaired malabsorptive conditions may 
also be at risk of vitamin D deficiency. This is often seen in patients suffering from 
severe liver failure, Crohn’s disease, Whipple’s disease and sprue. The inability to 
secrete adequate amounts of bile or conditions that damage the small intestine are 
characteristics of these disorders.76
Serum concentrations 25(OH)D is a good indicator of vitamin D status as it reflects 
both that obtained from sunlight and that of dietary sources and should therefore be 
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used as the primary indicator of vitamin D status. Its half life is approximately ten 
days to three weeks.76 Because of the short serum-half life of calcitriol (4-6 hours) 
and careful regulation of its production it is not a good indicator of vitamin D status.76  
Vitamin D concentration above 30ng/mL is considered optimal for good bone health, 
and “normal” reference range may include individuals with significant vitamin D 
insufficiency. Serum levels should be above 25-30 ng/mL in order to prevent 
consequences of vitamin D deficiency.77  
Vitamin K
Some evidence suggests that vitamin K may protect against age-related bone loss, 
mediated through the vitamin K-dependent γ-carboxylation of some proteins in bone 
(such as osteocalcin).65 Vitamin K deficiency results in undercarboxylated osteocalcin 
which is associated with decreased BMD and higher incidence of hip fractures.43
Vitamin K is obtained from dietary sources and from the synthesis of intestinal 
bacteria. American authorities recommend a dietary intake of 55-70 g of vitamin K 
per day. There are currently no recommendations for vitamin K intake from the 
Norwegian health authorities.  Deficiency in healthy individuals is rare. At risk 
patients are newborn, those with conditions leading to fat malabsorption and 
prolonged use of antibiotics.43
The Framingham heart study found a relationship between the incidence of hip 
fractures and dietary intake of vitamin K in elderly men and women assessed by food 
frequency questionnaire. They found increased incidence of fracture in those who 
reported low dietary intakes, but no effect on BMD.78
Vitamin C
Vitamin C is necessary for collagen cross linking and the collagenous structure of 
bone is weakened as a result of scurvy. In addition vitamin C along with other 
antioxidant may protect bone tissue from oxidative damage. This could be of 
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particular relevance in smokers who are at increased risk of developing bone 
disease.43
Vitamin A
All functions of vitamin A are thought to be mediated through the regulation of gene 
expression in several different types of cells.  Vitamin A is required for normal foetal 
development and for several other functions such as sight, cell differentiation and 
reproduction, haematopoiesis and differentiation of epithelial tissue. 
Vitamin A plays a role in bone remodelling. Both osteoblasts and osteoclasts have 
nuclear receptors for retinoic acid. Both deficiency and excess of vitamin A is 
believed to be detrimental to bone. Too high levels of vitamin A may increase bone 
resorption while vitamin A deficiency impairs osteoblast proliferation which causes 
excessive deposition of periosteal bone. It is therefore important to maintain adequate 
but safe levels of vitamin A intake to protect bone.43
Cobalamine, B12
B12 deficiency is associated with increased fracture risk and may be an important 
modifiable risk factor for osteoporosis.79 Malabsorption is often a result of altered gut 
function in the gastric pouch or sleeve, but can also occur when 60 to 100 cm of the 
terminal ileum is bypassed. B12 supplementation is often recommended to all bariatric 
surgery patients because deficiency is common. BPD-DS patients are likely to be less 
prone to deficiency compared to RYGB patients because a larger portion of the 
stomach is maintained which produces intrinsic factor necessary for its’ absorption. 
The distal part of the ileum also remains intact. Mild malabsorption of the vitamin 
may be corrected by oral supplementation of 350 g, but many require lifelong 
subcutaneous injections.28, 38
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6.1.2 Assessing bone health
Biochemical markers of bone metabolism
Collagen comprises about 90 % of the organic matrix. Thus how well the biochemical 
markers reflect the synthesis and degradation of type I collagen determines their 
representativeness of bone metabolism. The breakdown of bone causes increased 
renal excretion of its by-products including hydroxyproline, pyridinoline, 
deoxypyridinoline and N-telopeptide. 
In patients with significantly altered gastrointestinal function it is important to 
consider markers which reflect regulatory situations and those which reflect 
disturbances in bone metabolism. Serum levels of calcium, PTH, phosphate, 
magnesium, 25(OH)D and 1.25(OH)2D3 reflect the regulatory situation, while serum 
levels of bone markers such as bone-specific alkaline phosphatase, alkaline 
phosphatase, osteocalcin. I-CTP will reflect metabolic disturbances. Fasting urine 
levels of calcium/ creatinine ratio, DPYD and NTX will also reflect the latter. The 
concentration of ionized calcium in blood is strictly controlled, and therefore calcium 
can not be used as a general indicator of bone resorption.47
Urin-pyridiolin
Collagen consists of two alfa-1-chains and one alfa-2-chain attached in a triple helix. 
These structures are bound together by peptide bonds which will be released during 
bone resorption, and can be measured in urine as urin-pyridinolin.55
Alkaline phosphatase (ALP)
Alkaline phosphatase is an indicator of osteoblast activity. It is an enzyme associated 
with the plasma membrane of the osteoblast. ALP may be involved in extra cellular 
breakdown of pyrophosphate (which inhibits calcium phosphate deposition). It may 
be measured in serum using colorimetric methods. Its activity generally correlates 
with bone formation rate, for example in high or low turnover metabolic bone disease 
and during growth.47
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Type I collagen
Type I collagen is synthesised as a larger protein (type I procollagen), it contains an 
extra domain on each end of the molecule which prevent premature association of the 
collagen into fibrils before it has been secreted out into the extra cellular space. The 
extension domains are then released and can be quantified in blood where they are 
known as propeptides of type I collagen, often abbreviated as PINP for the amino 
terminal and PICP for the carboxy terminal. If bone matrix formation and 
mineralization are synchronized, as they normally are, there is correlation between 
serum carboxy terminal propeptide of type I procollagen (PICP) and mineralization 
rate. In osteomalacia these processes are uncoupled and there is no correlation 
between the two. This reflects the formation of unmineralized osteoid.47
Osteocalcin (bone GLA-Protein (BGP))
Osteocalcin is a gla protein which is incorporated into bone matrix during bone 
formation.  Osteocalcin is produced by the osteoblasts during the matrix 
mineralization phase. It’s expression is strongly controlled by calcitriol and is not 
produced in the absence of this hormone. Gla residues are assumed to bind calcium 
and to be directly derived from osteoblasts. Approximately 30 % of newly formed 
osteocalcin remains in the circulation and is hence used as a marker for bone
formation. However during bone resorption osteocalcin from bone is also released 
into the circulation, blood may contain osteocalcin from both formation and 
resorption. It may therefore be more appropriate to regard this protein as a marker of 
bone turnover rate rather than a formation marker.43
The biochemical indicators of bone resorption can be divided into two categories: 
Enzymes derived from the osteoclast and breakdown products of the organic matrix. 
The first category, biochemical markers of osteoclast function include tatrate-resistant 
acid phosphatase (TRAP). The other category, biochemical markers of bone matrix 
resorption, is a mixture of peptides and free amino acids from the breakdown of 
collagen fibres. (Risteli and Risteli 385-93) 
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C-terminal telopeptide of type I collagen (I-CTP)
I-CTP is the carboxy-terminal telopeptide region of type I collagen released during 
the degradation of mature type I collagen. This peptide is found in blood, where it 
seems to be derived from resorption and degradation of loose connective tissues. 
Increased serum concentrations of I-CTP are hence seen in conditions associated with 
increased lysis of bone, such as multiple myeloma, osteolytic metastases, rheumatoid 
arthritis and e.g. immobilization. In metabolic bone disease I-CTP concentration in 
serum correlates well with bone resorption rates. This is also true for osteomalacia 
and hyperthyroidism. 46
Calcitonin (CT)
Calcitonin is a peptide hormone with binding sites in the kidney, bone and central 
nervous system. It is released from the thyroid gland in respond to the rise in serum 
calcium concentration and in response to gut hormone signalling. CT slows or halts 
osteoclastic resorption, thus stopping calcium release from bone. When calcium 
absorption stops CT concentrations fall.  In skeletal tissue CT inhibits differentiation 
of osteoclasts and their resorptive properties.80
Parathyroid hormone (PTH)
PTH is a peptide with 84 amino acids. It is normally produced in the parathyroid 
glands which are located behind glandula thyreoidea in the neck. Calcium sensing 
receptors control the secretion and synthesis of PTH according to plasma calcium 
concentrations. The parathyroid glands are stimulated by a decline in calcium 
concentrations and their size and activity may increase by hyperplasia secondary to 
prolonged hypocalcaemia. An increase in serum-phosphate will also increase its 
production.
PTH helps maintain blood calcium levels by regulating bone turnover. A fall in
plasma calcium concentrations stimulates the release of PTH from the parathyroid 
gland. PTH increases renal phosphate clearance, increases renal tubular reabsorption 
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of calcium and activates bone resorption.  PTH promotes synthesis of calcitriol which 
then stimulates intestinal calcium absorption and regulates the synthesis of PTH by 
negative feedback. 76 This negative feedback loop ensures rapid response to correct
hypocalcaemia, but in situations of a chronically deficient diet it has serious 
consequences in bone tissue.48  
PTH effects bone tissue through stimulation of the osteoblasts. This leads to the 
release of several growth-factors, which in turn lead to an activation of osteoclasts. 
The net effect is increased bone turnover.
Modern methods of analysis use “two sites” antibody technique (IRMA) targeted at 
both the N- and C-terminal. This method has high sensitivity and specificity, and has 
made it easier to identify disturbances in calcium metabolism.
Table 39.  Overview of established biochemical markers of bone 
metabolism and their origin.
Biochemical markers of bone metabolism 
Cellular markers in serum 
(enzymes released by bone cells)
Matrix markers in serum 
(agents from bone matrix )
Matrix markers in urine
Formation 
markers
Alkaline phosphatase (ALP) PICP (Propeptide of type I procollagen)
Bone-specific alkaline phosphatase (b-ALP) PINP (propeptide of type I procollagen)
Osteocalcin
Resorption 
markers
Tatrate-resistant acid phosphatase (TRAP) 1-CTP Hydroxyproline
Pyridinoline & 
deoxypyridinoline cross-
links?
Pyridinoline &
deoxypyridinoline cross-links
INTP
Source:47
The pro-peptide parts of type I procollagen reflect the deposition of new type I 
collagen, while the non-collagenous indicators of osteoblast activity are alkaline 
phosphatase and osteocalcin. In a steady state situation, there should be reasonable 
correlations between all these markers, but they represent different phases of the 
osteoblast.
Other hormones in bone metabolism
Cytokines are locally acting hormones which facilitate changes in calcium 
metabolism. Immune cell products such as lymphotoxin, tumour necrosis factor 
(TNF) and the interleukins promote bone resorption. Several osteotrophic cytokines 
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may have a role in bone remodelling. Among the factors capable of stimulating bone 
resorption are tumour necrosis factor α and β, transforming growth factors, platelet 
derived growth factor, and arachidonic acid metabolites such as prostaglandins and 
leukotrienes. 48
6.1.3 Measuring bone mineral density
Bone mineral density (BMD) is a measured calculation of the true bone mass (g/cm2). 
In populations BMD correlates with bone strength, its ability to bear weight and 
tolerate impact, however this may vary between individuals. BMD measurements are 
used to predict the risk of bone fracture.
The World Health Organization has defined specific diagnostic categories for 
assessing bone health. However the reference population used in interpreting BMD is 
based on Caucasian data and there is significant variation in BMD between ethnic 
groups. For example, persons of African descent tend to have a greater BMD 
compared to those of Caucasian and Asian descent. This should be taken into account 
when interpreting BMD results 49
Dual energy x-ray absorptiometry (DXA) is recognised as the most accurate method 
of measuring bone mineral density. This method uses the fact that a (foton) beam is 
weakened when it passes through bone tissue. To correct for surrounding soft tissue 
two foton beams with different energy levels are used. Common assessment areas are 
underarm, columna lumbalis and columna femoris. Bone mineral content (BMC) is 
the most important single risk factor in relation to osteoporosis. BMC changes 
according to rate of bone metabolism, because the remodelling space changes. If bone
metabolism increases a fall in BMC can be seen. There is a clear relationship between 
BMC and fracture risk on population level, but as BMC only to a limited degree is 
related to biomechanical strength, BMC measurement in individuals can not predict 
future risk for developing osteoporosis accurately.69 Results are defined in T-score 
and Z-score. On population level there is a two to three fold increase in the incidence 
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of spinal fractures in patients with low BMD. A BMD in the osteoporosis range, 
implies approximately 5 times increased fracture risk
T-score is the standard deviation from the mean BMD of a reference population 
(young healthy adults in their peak bone density years). Table 40 shows the WHO use 
of the T-score to define diagnostic criteria of metabolic bone disease. 
Table 40. DXA T-score classification as a diagnostic tool for osteoporosis.
T-score 
T-score =/> -1 Normal bone density
T-score between -1 and -2.5 Low bone mineral density (osteopenia)
T score =/< -2.5 Osteoporosis if a fragility fracture has occurred 
(established) or severe osteoporosis is present. 
Source: 49
These criteria only apply to DXA of the posterior-anterior spine, femoral neck, and 
the proximal radius (33%) radius in post-menopausal women and men over the age of 
50 years.
The z-score is the patients BMD expressed in SD from the mean of a reference 
population (a healthy reference population of the same gender and age) and should be 
used instead of the t-score for pre-menopausal women and men under the age of 50. 
If BMD is solely a result of normal aging process, the z-score will be close to zero. If 
the z-score is less than -1.5, secondary causes of bone disease should be considered. 
All patients with a z-score below -2.0 should be evaluated for necessary treatment 
therapy.28
Williams et al recommended that all bariatric surgery patients have pre-operative 
DXA measurements as part of their evaluation and that measurements are conducted 
at 12 month intervals post-operatively, particularly in the first few years when 
metabolic change is most dramatic.28
Newer DXA machines tolerate weights up to 204 kg as opposed to the older ones 
which had a limit of 125 kg. For those who cannot be accommodated on a dxa table, 
dxa of the forearm may be used to assess bone density and fracture risk.49
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Appendix 2   
Structured interview with student clinical nutritionist
 Konsultasjon – Huskeliste
1. BES- skjema utleveres mellom konsultasjonene, slik at de kan fylle den ut mens de venter. 
2. Subjektivt intervju – eget ark
3. DS konsultasjon – eget ark
5. Pedometer 
vis og forklar
bestemme hvilke 3 dager de skal gå med den. 
6. Matdagbok
Instruksjoner for matdagbok: Bruk mal for instruksjoner + sette opp plan for hvilke 
dager den skal fylles ut.
7. IPAQ
Insturksjoner for utfylling av spørreskjema om fysisk aktivitet
Denne kan de ta med hjem å fylle ut etter at de er ferdig med kostdagbok og
pedometer. 
8. Blodprøverekvisisjoner
3 skjemaer må sendes med
9. DEXA- rekvisisjon
Henvisning sendes med. 
10. Samtykkeskjema – invitasjon til å være med i studien
 2. Subjektivt intervju
 Har matlysten/ appetitten din endret seg sammenlignet med før operasjonen?
 Har matlysten/ appetitten din endret seg det siste året?
 Opplever du begrensninger ved måltid med tanke på mengder/ porsjonsstørrelser du 
kan ta i ett måltid? 
 Reagerer du på fettrik mat?
o Hvis ja, hvordan reagerer du?
 Har du opplevd smaksforandringer?
 Opplever du søtsug?
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o Hvis ja, hvordan takler du dette?
 Er det noe du ikke tåler lenger?
o I så fall hva? Og hvordan reagerer du?
 Er du plaget av:
o Diare/ forstoppelse?
o Kvalme/ oppkast?
o Tygge/ svelgeproblemer?
 Er det sosiale situasjoner som påvirkes?
3. DS konsultasjon
 Kartlegging av måltidsytme/ mønster
o Hovedmåltider 
o Mellommåltider
o Inntak mellom måltidene
o Væske både til og mellom måltidene.
 Tilskudd
o Hvilke tabletter tar du, hvor ofte, og hvor mange av hver?
Tilskudd  Hvor 
ofte
Antall per gang Tot antall per dag
Multivitamineraler
(med zink og magnesium?)
eks. Nycoplus Multi
Spesifiser:
Calcigran forte tyggetablett
Hvis annet kalsium tilskudd, 
spesifiser:
AFI D 2 Forte
Ferromax (65mg)
(kvinner i fertil alder)
Hemofer
Omega 3 m/ folat
B12 injeksjon
Zink (mangel/ hårtap)
K-vitamin
Idoform (v/ diare)
Imodium (v/ diare)
Bio-dophilus, naturlige 
tarmbakterier
*kalsium og jern bør ikke tas samtidig (konkurerer om opptak)
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o Hender det at du ikke tar enkelte tilskudd? 
I så fall, hvor ofte? 
Hvilke? 
Hvorfor?   
o Opplever du vanskeligheter med tilskuddene?
Er de vanskelig å huske på?
Er de vanskelige å svelge?
 Proteininntak
o Forenklet kostanamnese med fokus på proteinholdige matvarer
 Husk: pålegg, middag, meieriprodukter.
 Evt gi enkle råd og svar på spørsmål
 Væskeinntak
Hva og hvor mye drikker de?
Anbefal minst 2 liter per dag, helst mellom måltidene. 
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Appendix 3
Food diary









Appendix 4
Information about food diary
Informasjon om Matdagboken
Dette er matdagboken som fylles ut i løpet av de neste 2 ukene. Den første uken registrerer du alt i 
__ dager etter hverandre, og den andre uken registrerer du alt i__ dager etter hverandre. Til sammen 
registrerer du alt du spiser i 7 dager. I den første konvolutten ligger skjemaene du skal fylle ut i den 
første uken, og i den andre konvolutten ligger skjemaene du skal fylle ut i den andre uken. Til 
sammen er det 7 skjemaer som skal fylles ut – en for hver dag. 
Det er viktig at du er nøye med registreringen, og fyller inn alt du spiser. Det inkluderer mat og 
drikke til hovedmåltidene, mellommåltidene og det du spiser og drikker utenom disse. 
Ingen restriksjoner
Det er også viktig at du ikke forandrer på kosten din på grunn av matdagboken. Du har ingen 
restriksjoner utenom det du har fra før. 
Les nøye
I spørreskjemaene er det grundige forklaringer til hver seksjon. Leser du nøye gjennom alt som står 
i hver av seksjonene, vil du unngå misforståelser. Mye av det du lurer på, vil du også finne svar på 
her. 
De oransje rutene
I matdagboken vil du se at det flere steder er en oransje rute ved siden av rutene for antall matvare. 
I disse rutene fyller du inn bokstaven for porsjonsstørrelse som passer til det du har spist. For å 
bestemme porsjonsstørrelse bruker du det oransje hefte, der finner du bilder av forskjellige 
porsjonsstørelser, og en bokstav som hører til hver størrelse. Dette gjøres hver gang det er en 
oransje rute ved siden av en matvare du har spist og fylt inn. 
Pålegg
I seksjonen for pålegg registreres mengden i forhold til antall skiver. Hvis du bruker mer pålegg en 
det som er vanlig på en skive, må du ta dette i betraktning. Registrer mengden i forhold til det du 
tar. Hvis du for eksempel bruker 2 skiver kokt skinke på en brødskive, isteden for 1 skive kokt 
skinke, må du skrive at du har spist kokt skinke til 2 brødskiver, selv om du bare har spist en 
brødskive. Antall brødskiver/ knekkebrød du har spist, registrerer du i en annen seksjon. Hvis du 
bruker ett tykt lag med leverpostei, som du tror vanligvis kan brukes til 2 skiver, må du skrive at du 
har spist leverpostei til 2 skiver. Hvis du har spist 2 skiver, som du hadde dobbelt opp med pålegg 
på, registrerer du dermed 4 porsjoner pålegg, altså pålegg til 4 skiver. Det samme gjelder for alt 
annet pålegg.
Kosttilskudd
Registrer alle kosttilskuddene du tar hver dag. Det er laget plass til å registrere disse på siste side i 
skjemaet, men du vil sannsynligvis finne at flere av kosttilskuddene du tar ikke er listet her. I så 
tilfelle kan du bruke baksiden av skjemaet til å skrive ned disse tilskuddene. Det er viktig at du 
registrerer hver eneste tablett, hver eneste dag. Hvis du ikke skriver de opp, går vi utifra at du ikke 
har tatt tilskudd. 
Spørsmål
Hvis du har problemer med å fylle ut matdagbøkene, bruk av skritteller, spøreskjemaet for fysisk 
aktivitet, eller du har andre spørsmål, er det bare å ta kontakt med Julia eller Nicole:
Kontaktinformasjon, Julia Kontaktinformasjon, Nicole
Telefon: 41046876 Telefon: 97789991
Mail: julia.mckenna@studmed.uio.no Mail: n.s.warmbrodt@studmed.uio.no
Appendix 5
Patient information and consent form.
Informasjon og forespørsel om deltakelse i forskningsprosjekt
Næringsstatus, næringsinntak og fysisk aktivitet hos pasienter operert med 
biliopankreatisk bypass med duodenal switch for fedme
Hensikten med denne studien:
Hensikten med denne studien er å kartlegge kosthold, fysisk aktivitet, ernæringsstatus, benstatus, 
potensielle kostrelaterte problemer og fedmerelaterte komorbiditeter hos duodenal switch 
pasienter 2 år eller mer etter operasjon.
Studien utføres for å øke kunnskapen rundt følgene av denne typen operasjoner, og dermed gi et 
bedre behandlingstilbud for denne pasientgruppen.
Hvorfor blir du forespurt
Du er blitt spurt om å delta fordi du har gjennomgått biliopankreatisk bypass med duodenal 
switch for fedme, det er 2 år eller lengre siden operasjonsdato, og du blir fulgt opp ved avdeling 
for preventiv kardiologi, UUS.
Frivillighet:
Det er frivillig å delta i studien. Dersom du velger å ikke delta, trenger du ikke oppgi grunn. Du 
kan når som helst trekke deg uten at dette vil påvirke den behandlingen du får ved Ullevål 
universitetssykehus. 
Hva innebærer dette for deg:
Mye av det du må gjøre i forbindelse med prosjektet inngår allerede i ditt behandlingsopplegg her 
ved Ullevål universitetssykehus. Blodprøver, dexa måling (mål på bentetthet) og ett spørreskjema 
er standard prosedyre, men du vil i tillegg bli bedt om å fylle ut en kostdagbok og et spørreskjema 
om fysisk aktivitet og gå med en skritteller i 3 dager. 
Når du er ferdig med utfylling av kostdagbok og skrittellerskjema, må du returnere disse til oss.
Vi ber om din tillatelse til at disse opplysningene fra din journal, brukes i forskningsprosjektet: 
alder, kjønn, vekt, resultater fra blodprøvetaking og DEXA- målinger.
Slik ivaretas dine prøver og personopplysninger:
Alle opplysningene vil bli behandlet konfidensielt. I prosjektet har du et prosjektnummer som 
knytter deg som person til prosjektinformasjon gjennom en egen liste. Kun prosjektansvarlige 
med taushetsplikt har adgang til adresselisten. Alle opplysningene som inngår i prosjektet vil bli 
oppbevart i et eget datasystem ved sykehuset i tråd med interne retningslinjer for datasikkerhet.
Hvor lenge skal materiale og opplysninger lagres?
Når prosjektet avsluttes i november 2008 vil gjenværende materiale og informasjon bli 
destruert/slettet etter gjeldende retningslinjer. Du har rett til å se de personlige dataene som er 
samlet inn om deg og få dem rettet hvis noen er feil. Dersom du ikke lenger vil være med i 
studien kan du forlange analyseresultatene slettet, og da kan du også forlange at prøvene som er 
tatt av deg i forbindelse med forskningsprosjektet skal ødelegges.
Annet 
Når du deltar i denne studien vil du være forsikret mot uforutsette skader forårsaket av studien 
etter gjeldende bestemmelser i Norge (pasientskadeerstatningsordningen). Undersøkelser i 
studien vil ikke medføre kostnader for deg. Vi dekker ikke tapt arbeidsfortjeneste. 
Forskningsetiske komite i Helseregion Øst har vurdert utprøvingen og funnet at den tilfredstiller 
de krav som forskriftene stiller.
Prosjektansvarlig/Mer informasjon
Hvis du har spørsmål om studien, kan du kontakte overlege Serena Tonstad. Hun vil være beredt 
til å svare på dine spørsmål på telefon: 22119979.
SAMTYKKE- PROSJEKTDELTAKELSE
Deltakelse i studien er basert på ditt frivillige, informerte samtykke. Dersom du ønsker 
informasjon utover det som framkommer i dette informasjonsskrivet og den muntlige 
informasjon du har mottatt, har du full anledning til å be om dette. Dersom du etter å ha fått den 
informasjonen du synes er nødvendig, sier ja til å delta i studien, må du signere 
samtykkeerklæringen:
Jeg bekrefter at jeg har mottatt den informasjonen (skriftlig og muntlig) om prosjektet som jeg 
synes er nødvendig og sier ja til å delta i studien:
Forsøkspersonens etternavn og fornavn:………………………………..
Dato: / 2006               ………………………………… (signatur)
Muntlig bekreftelse: Jeg bekrefter at jeg på en korrekt måte har informert
……………………………….. om hensikten og hvordan studien skal gjennomføres:
Dato: / 2006 ………………………………. (signatur)
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UUS’ meldeskjema for forsknings-, kvalitetsstudier og annen aktivitet 
som medfører behandling av personopplysninger som er melde- eller 
konsesjonspliktig i henhold til helseregisterloven og 
personopplysningsloven med forskrifter
Utfylt skjema sendes elektronisk til sykehusets personvernombud: heidi.thorstensen@ulleval.no
Spørsmål ifm utfylling av skjemaet kan sendes til: heidi.thorstensen@ulleval.no
1 INFORMASJON OM SØKEREN
A. BEHANDLINGSANSVARLIG VIRKSOMHET
Ullevål universitetssykehus HF Organisasjonsnummer
9 8 3 9 7 1 7 8 4
Postadresse
Kirkeveien 166
Postnr.
0407
Sted
Oslo
Land   Norge
Telefonnummer
22118080
Telefaksnummer
22119950
E-postadresse/hjemmeside
www.uus.no
B. DIVISJON/AVDELING VED UUS HVOR PROSJEKTET GJENNOMFØRES
Avdeling for preventiv kardiologi
C. DAGLIG ANSVAR FOR OPPFYLLELSE AV DEN BEHANDLINGSANSVARLIGES PLIKTER ER ADMINISTRERENDE DIREKTØR
D. PROSJEKTETS KONTAKTPERSON (må være ansatt ved UUS)
Navn og stilling ved UUS
Professor Serena Tonstad, overlege ved anvdeling for preventiv kardiologi
Telefonnummer
22117939
E-postadresse
Serena.Tonstad@uus.no
E. MULTISENTERSTUDIE1
Er prosjektet en multisenterstudie? Nei   Ja  Dersom ja, angi øvrige virksomheter som deltar.
Skal noen av disse også ha kopi av elektronisk database/informasjon som etableres i prosjektet?  Nei   Ja 
F. LEGEMIDDELFIRMA ELLER ANNEN VIRKSOMHET HAR KONSESJON FOR PROSJEKTET
Er prosjektet organisert fra et legemiddelfirma eller annen virksomhet som allerede har konsesjon? 
Nei   
Ja  Dersom ja, angi virksomhetens navn. (Kopi av konsesjonen skal sendes UUS’ personvernombud, og prosjektet skal meldes 
personvernombudet som meldepliktig prosjekt, dvs skjemaet fylles ut med unntak av punktene 8.4, 8.5, 9 og 10.)
Skal den eksterne også ha kodelisten/navnelisten over deltakere inkludert fra UUS?  Nei   Ja
Dekker denne meldingen utlevering av opplysninger fra UUS til firma/virksomhet som har konsesjon?  Nei   Ja 
                                                
1 For å merke av i boksene, dobbeltklikkes det på venstre museknapp med markøren på boksen som skal avkrysses. I 
dialogboksen som kommer frem, velges ”aktivert”. Ved å gjenta prosessen og klikke på ”deaktivert” fjernes krysset
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2 PROSJEKTETS NAVN/TITTEL
Næringsstatus, næringsinntak og fysisk aktivitet hos pasienter operert med biliopankreatisk bypass med duodenal switch for fedme. 
3 BESKRIV FORMÅLET MED BEHANDLINGEN/PROSJEKTET2
Formålet med studien er å kartlegge kosthold, fysisk aktivitet, ernæringsstatus, benstatus, potensielle kostrelaterte problemer og 
fedmerelaterte komorbiditeter hos duodenal switch pasienter, to år eller mer etter operasjon. Med dette håper vi å øke kunnskapen 
rundt disse faktorene som kan bidra til å forbedre oppfølgingstilbudet til denne pasientgruppen. 
4 BEHOV FOR KONSESJON ELLER MELDING
4.1 Meldepliktige prosjekter – Siden UUS har internt personvernombud, vil de fleste studier være meldepliktige
Ett av de tre hovedpunktene må være oppfylt for at studien skal være meldepliktig:
- Prosjektet er omfattet av personopplysningsforskriften § 7-27. (Punkt a under må være oppfylt, samt enten b eller c)
   a) Tilrådd av personvernombud, og REK for prosjekter med medisinsk eller helsefaglig forskning. 
   b) Ikke stort omfang, men lang varighet og identifiserbart, eller
   c) store datasett og tilfredsstillende avidentifisert eller pseudonymisert.
- Prosjektet/behandlingen har hjemmel i lov utføres i regi av organ i stat eller kommune (eks. kvalitetssikring etter 
    helsepersonellovens § 26) – se personopplysningsloven § 33, fjerde ledd.
- Prosjektet er regulert i forskrift som spesielt angir at det er unntatt fra konsesjonsplikt eller underlag meldeplikt (f.eks. de sentrale  
   helseregisterforskriftene)
                                                
2 Behovet for konsesjon/melding er knyttet opp til hvilket formål man har med behandlingen av personopplysningene. UUS’
journalsystemet er i sin helhet meldt, og har lovhjemlet formål. Når informasjon i journalsystemet skal benyttes til andre 
formål, kommer behovet for konsesjon, alternativt ny melding, opp, og man må angi formålet med den nye 
bruken/behandlingen av personopplysningene. Formulering av formålet er derfor viktig. Tilsvarende gjelder for annen 
innsamling og behandling av pasient-/personopplysninger. Formålet må samsvare med det som beskrives i samtykket fra hver 
enkelt person som deltar i studien.
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4.1.1 Avklaringspunkter3:
  Nei Ja  Respondenten eller verge samtykker i alle deler av undersøkelsen (formål og varighet på oppbevaring av personopplysningene)
  Nei Ja  Det benyttes kobling mot andre personregistre, eks fødselsregister, kreftregister, dødsårsaksregister eller tilsvarende         
  Nei Ja  Studien inkluderer et stort omfang av personer og/eller data – dvs mer enn 5000 og/eller opplysninger av svært inngripende karakter
                          Angi totalt inkluderte
                          Angi hvilke type opplysninger som vurderes til å være av svært inngripende karakter  
  Oppgi i feltet under tidspunkt for når studien avsluttes og personopplysningene slettes eller anonymiseres (kodelisten slettes). Dersom det er 
vanskelig å angi tidspunkt, skriv i feltet under en tekstforklaring sammen med antatt tidspunkt.
                          NB! Husk på å inkludere tid for innsamling, bearbeiding og publisering ved angivelse av tidspunkt.
  Det innsamlede materiale skal ved angitt tidspunkt slettes eller anonymiseres (kun et av alternativene anonymisering eller sletting skal avkrysses)
   Nei Ja    anonymiseres, forklar hvordan 
   Nei Ja    slettes ved prosjektavslutning
   Nei Ja  Personopplysninger, inkludert avidentifiserte/kodede, lagres kun på papir.
ELLER
4.1.2 Intern kvalitetsoppfølging
  Nei Ja  Oppfyller Helsepersonelloven § 26 
                                   Opplysningene må være slettet eller anonymisert før eventuell publisering av resultater.
                                    Krever ikke samtykke, ref punkt 8, Personopplysningsloven § 33 4. ledd gir unntak for konsesjon men krever melding.
                                    Pasienter som har reservert seg mot slik bruk av opplysningene, skal respekteres.
  
ELLER
4.1.3 Annet som hjemler melding, angi årsak/hjemmel
Dersom meldepliktig studie, besvares ikke punktene 9 og 10.
4.2 Konsesjonspliktig prosjekt
            Dette punktet benyttes av sykehusets personvernombud dersom studien er konsesjonspliktig
Ja  -  Prosjektet tilfredsstiller ikke forutsetninger for melding (se punktene under 4.1) og må ha konsesjon
5 PROSJEKTPERIODE
Ny melding, angi dato
SVAR:
Oppdatert melding (forutsetter samme formål som forrige melding), angi dato
SVAR:
Angi dato for prosjektavslutning. NB! Må inkludere innsamling, analyse/vurdering, artikkelskriving/konklusjon og eventuelt tid for oppbevaring 
etter ferdigstilling. Dette gir dato for sletting/anonymiseringer av personopplysningene.
SVAR: November 2008
                                                
3 For å merke av i boksene, dobbeltklikkes det på venstre museknapp med markøren på boksen som skal avkrysses. I 
dialogboksen som kommer frem, velges ”aktivert”. Ved å gjenta prosessen og klikke på ”deaktivert” fjernes krysset
November 2008
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Eventuelle tilleggskommentarer:
6 HUMANT, BIOLOGISK MATERIALE
Medfører prosjektet bruk av humant, biologisk materiale, som tas kun for denne studien, dvs ikke i diagnostisk eller behandlingsmessig hensikt?
Nei 
Ja   -  Forskningsprosjekt vil da alltid måtte etablere biobank
               (Kvalitetssikringsprosjekt, ref HPL § 26 vil benytte diagnostisk/behandlingsmessig biobank og trenger ikke melde forskningsbiobank.)
7 DETALJER OM PROSJEKTETS INFORMASJONSBEHANDLING
7.1 Behandlingen skal omfatte typer personopplysninger:
7.1.1 Ikke-sensitive personopplysninger
Identifikasjonsopplysninger 
  Navn, adresse, fødselsdato
  Fødselsnummer (11 siffer)
  Fingeravtrykk, iris
  Annet
Atferdsopplysninger
  Loggføring av adferd, herunder tidspunkt og sted for handlinger
  Preferanser (ønsker, behov o.l.)
  Annet
Opplysninger om tredjepersoner
  Navn, adresse, fødselsdato
  Fødselsnummer (11 siffer)
  Annet
Fjernsynsovervåkning og lydopptak (sett eventuelt. flere kryss)
  Fjernsynsovervåkning                
  Billedopptak
  Lydopptak
7.1.2 Sensitive personopplysninger, jf. pol. § 2 nr. 8
Behandlingen omfatter opplysninger om
  rasemessig eller etnisk bakgrunn, eller politisk, filosofisk 
        eller religiøs oppfatning
  at en person har vært mistenkt, siktet, tiltalt eller dømt for en
        straffbar handling
  helseforhold
  seksuelle forhold
  medlemskap i fagforeninger. 
Ved konsesjonssøknad, presiser nærmere: (eventuelt i eget vedlegg)
Behandling av sensitive personopplysninger:
  skjer helt eller delvis med elektroniske hjelpemidler
  som kun inngår eller skal inngå i et manuelt personregister
7.2 Behandlingen omfatter opplysninger om (beskriv også eventuell kontrollgruppe)
Ansatte i egen virksomhet
Adgangskontrollerte
Annet: (skriv inn i feltet nedenfor)
Elever/studenter/barnehagebarn
Medlemmer
Pasienter
Kunder/klienter/brukere
Tilfeldig utvalgte
Seleksjonsutvalg
Angi størrelsesorden på utvalget 
Inkluderer utvalget personer med begrenset samtykkekompetanse, eks mindreårige, demente, annet,  Nei Ja    Dersom ja, forklar
  
7.3 Hvordan samles personopplysningene inn?
Manuelt                            Annet: (skriv inn i feltet nedenfor) 
Elektronisk  (bilde og tekst)
Videoopptak
Lydopptak
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7.4 Personopplysningene innhentes fra
Fra den registrerte selv 
Annet: (skriv inn i feltet nedenfor)
7.5 Hvordan skal opplysningene brukes?
Registreres
Lagres
Sammenstilles, med hva
(eksterne registre eller interne 
konsesjonsbelagte registre):
Utleveres, til hvem:
Annet:
(skriv inn i feltet)
7.6 Lagring og behandling av opplysninger – utstyret som benyttes, skal alltid eies av UUS dersom ikke annet er oppgitt
Elektronisk –
      På server i UUSs nettverk
      Angi navn på server,     
Dersom UUS – forsk-
ningsserver benyttes, er 
risikohåndtering og 
sikkerhet beskrevet i 
UUS standard vedlegg 2 
og 3, – henvis til dem.
Elektronisk –
På frittstående PC eiet av UUS 
(dvs ingen tilknytning til andre 
PC-er eller nettverk, interne 
eller eksterne)
Forklar hvordan PC er sikret
Papir –
Forklar hvordan dette sikres 
mot uvedkommende
Video, tape eller annet opptak   
Beskriv hva og hvordan dette 
er sikret mot uvedkommende 
og om personen kan 
identifiseres
Annet, angis i feltet
Fra pasientjournal
UUS – forskningsserver
Se UUS standard vedlegg 2 og 3
Enkelte parametre skal sammenlignes med verdier fra tidligere i pasientens behandlingsperiode.
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7.7 Hvordan gjenfinnes opplysningene? Bruk av direkte identifisering som personnummer og navn skal søkes å unngå,  se  
sykehusets instruks i den kliniske håndboken
         Opplysningene lagres med navn, personnummer eller annet som entydig angir det enkelte individ  Nei Ja
         Opplysningene lagres avidentifisert  Nei Ja
         Hvordan er krysslister/kodelister beskyttet/lagret (skriv inn i feltet under)
7.8 Blir personopplysningene gjort tilgjengelige/utlevert til andre
Nei
Ja, oppgi mottakeres navn og 
adresse, samt hvilken rolle mottaker har 
i prosjektet. (Videre utfylling i punkt 
7.8 skal bare gjøres dersom dette er 
besvart med JA.)
Kryss av dersom opplysningene 
overføres til utlandet?  Ja
Hva blir overført?
         Informasjon med navn, personnummer eller annet som entydig angir det enkelte individ?  Nei Ja
         Avidentifisert informasjon?  Nei Ja (Forklar i feltet under hvordan kryssreferanseliste beskyttes dersom dette ikke er likt som i pkt 7.7)
         Anonymisert informasjon?  Nei Ja
         Annet? (Forklares i feltet under, eksempelvis hvordan opptak håndteres.)
Hvordan oversendes informasjonen?
         Overført til diskett eller tilsvarende og sendt i vanlig postgang?  Nei Ja         
         Sendt over eksterne linjer?  Nei Ja
         Hvordan er det sikret mot uautorisert avlytting? (Forklares i feltet under)
         Annet? (Forklares i feltet under)
Er det inngått avtale med mottaker, slik at personvernet er sikret ved oversendt informasjon?  Nei Ja 
7.9 Annen årsak til overføring i eksternt datanett
Overføres opplysningene i eksternt datanett ut over det som er spurt om i 7.8?  Nei Ja         Dersom ja, forklar
Kodelistene vil lagres i ett excel ark på en passordbeskyttet UUS PC, som er låst inne på ett kontor ved 
avdeling for preventiv kardiologi. 
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8 RETTSLIG GRUNNLAG FOR BEHANDLING AV PERSONOPPLYSNINGENE
Som hovedregel skal informert samtykke innhentes. Dersom personens helse eller annen tilstand umuliggjør dette, kan det likevel 
søkes konsesjon. Det må da utdypes
 hvordan ulempen for den enkelte og personvernet alternativt håndteres
 hvilke samfunnsmessig interesse gjennomføring av prosjektet innebærer
8.1 Behandling av personopplysninger i henhold til
         personopplysningsloven § 8 
(Gjelder ikke-sensitive personopplysninger)
med den registrertes samtykke
ved at det er fastsatt i lov at det er adgang til slik behandling
for å oppfylle en avtale med den registrerte, eller utføre 
      gjøremål etter den registrertes ønske før en slik avtale skal
      inngås
for at den behandlingsansvarlige skal kunne oppfylle en 
      rettslig forpliktelse
for å utføre en oppgave av allmenn interesse
for å utøve offentlig myndighet
for at den behandlingsansvarlige eller tredjepersoner som 
      opplysningene utleveres til kan vareta en berettiget interesse,
      og hensynet til den registrertes personvern ikke overstiger
      denne interessen
8.2 Behandling av personopplysninger i henhold til
         personopplysningsloven § 9 
(Gjelder sensitive personopplysninger)
med den registrertes samtykke 
når det er fastsatt i lov at det er adgang til slik behandling
når behandlingen er nødvendig for å beskytte en persons 
      vitale interesser, og den registrerte ikke er i stand til å
      samtykke
når det utelukkende behandles opplysninger som den 
      registrerte selv frivillig har gjort alminnelig kjent
når behandlingen er nødvendig for å fastsette, gjøre gjeldende
      eller forsvare et rettskrav
når behandlingen er nødvendig for at den
      behandlingsansvarlige kan gjennomføre sine arbeidsrettslige 
      plikter eller rettigheter
når behandlingen er nødvendig for forebyggende  
      sykdomsbehandling, medisinsk diagnose, sykepleie eller 
      pasientbehandling eller for forvaltning av helsetjenester, og 
      opplysningene behandles av helsepersonell med 
      taushetsplikt
når behandlingen er nødvendig for historiske, statisktiske 
      eller vitenskapelige formål, og samfunnets interesse i at 
      behandlingen finner sted klart overstiger ulempene den kan 
      medføre for den enkelte
i henhold til personopplysningsloven § 9 annet ledd 
8.3 Hvordan skal informasjonsplikten i POL §§ 19 og 20 oppfylles? Se sykehusets instruks for krav til innhold
Når opplysninger samles inn fra den registrerte                    
Når opplysninger samles inn fra andre enn den registrerte   
Muntlig      
Muntlig      
Skriftlig            
Skriftlig            
Legg ved kopi av dokumentasjonen
8.4 Annet grunnlag for behandlingen?
Forklar, for eksempel HPL § 26, se punkt 4.1.2:
8.5 Andre tillatelser
Fremleggingsplikt for REK             Nei   Ja   
Dispensasjon fra taushetsplikten     Nei   Ja      Hvis ja, legg ved/ettersend dispensasjonen
Andre tillatelser, forklar og legg ved/ettersend
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9 OPPFYLLELSE AV ENKELTE BESTEMMELSER I PERSONOPPLYSNINGSLOVEN
9.1 Hvordan skal det sikres at opplysningene er tilstrekkelige og relevante i forhold til formålet med behandlingen? Legg ved en beskrivelse av 
rutinen. 
Opplysningene som hentes inn er del av behandlingen for duodenal switch opererte ved avdeling for preventiv kardiologi, UUS. Se 
vedlegg: Konsultasjon - huskeliste
9.2 Hvordan skal det sikres at opplysningene er korrekte og oppdaterte i forhold til formålet med behandlingen. Legg ved en beskrivelse av 
rutinen.
Opplysningene som hentes inn er del av behandlingen for duodenal switch opererte ved avdeling for preventiv kardiologi, UUS. Se 
vedlegg: Konsultasjon - huskeliste
9.3 Hvordan skal det sikres at opplysningene slettes når formålet er oppfylt? Legg ved en beskrivelse av sletterutinen. 
9.4 Hvor lenge må opplysningene være identifiserbare, angis med måned og år:
Til tiden for prosjektet må det inkluderes tiden det tar å gjennomføre innsamling av opplysninger, bearbeiding av opplysningene, 
konkludering, utforming av eventuelle artikler og eventuelle krav om oppbevaring etter publisering.
9.5 Er det meningen at opplysningene skal oppbevares etter at formålet er oppfylt, dvs etter tid angitt i punkt 9.4?
                                                                                                                                                       Nei   Ja      Hvis ja; angi grunnlag:
i medhold av arkivloven
annen lovgivning, hvilken lovhjemmel:
historiske etter statistiske formål
vitenskaplige formål
Dersom opplysningene behandles for historiske, statistiske eller vitenskapelige formål, legg ved en beskrivelse av de samfunnsinteresser 
som vil oppveie personvernulempene.
Presiser nærmere: (eventuelt i eget vedlegg)
10 INFORMASJONSSIKKERHET
UUSs sikkerhetsmål, sikkerhetsstrategi og sikkerhetsorganisering se VEDLEGG 1 (vedlegges konsesjonssøknad)
UUS risikovurdering og etablert forskningsserver, se VEDLEGG 2 og 3 (vedlegges konsesjonssøknad)
UUS har internkontrollsystem
Utføres behandlingen i henhold til annet regelverk som regulerer sikkerheten. 
Nei 
  Ja      Hvis ja; hvilket regelverk.
11 Underskrift
Sted og dato
Oslo, 21 sep 06
Underskrift
Serena Tonstad
2 år, 2 måneder
